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 Ceramide is an amphiphilic natural product that plays important roles in 
multiple cellular processes.  Ceramide also is known to self-assemble into 
transmembrane pores under physiologically relevant concentrations.  In order to study 
the role of ceramide’s 1,3-diol functionality in the stabilization of transmembrane 
pores, ceramide analogs were prepared using protecting groups to block the 1,3-diol 
unit.  Blocking the 1,3-diol with an acetal protecting group led to a drastic decrease in 
membrane-activity.  Surprisingly, blocking the –OH groups of C2-ceramide 2 with 
simple esters yielded a C2-diacetate 16 analog with increased pore-forming activity. 
 Additionally, a new function of C2-ceramide 2 has been discovered that has 
important biological implications.  Working below concentrations in which it self-
assembles into transmembrane pores, C2-ceramide 2 facilitated the transmembrane 




 via an anion exchange 
mechanism.  The 1,3-diol functionality of the C2-ceramide 2 headgroup was found to 
  
play an integral role in the binding and transport of anions, as the isopropylidene C2-
ceramide 18 analog was unable to facilitate transmembrane anion transport. 
 D-erythro-Sphingosine 3, produced naturally by the metabolism of ceramide, 
lacks the amide functionality in its hydrophilic head-group.  Unlike C2-ceramide 2, 




 exchange.  Possible 
reasons for this failure to facilitate the transmembrane transport of anions are 
discussed, namely that sphingosine 3 does not bind HCO3
-
 in a non-covalent manner.  
Instead, sphingosine 3 forms carbamates in the presence of HCO3
-
 and CO2 in a 
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Chapter 1 : Bioorganic Chemistry of Sphingolipids 
 
1.1 Introduction 
 The compounds C16-ceramide 1 and C2-ceramide 2 are sphingolipids that 
consist of a sphingosine 3 base connected via an amide linkage to an aliphatic fatty 
acid chain.   Ceramides are involved in the regulation of a range of important cellular 
processes including cell differentiation, autophagy, cell senescence, skin water barrier 
homeostasis, and apoptosis.
1-5
  Due to the fact that ceramides are so important for cell 
metabolism, there is a need to better understand the molecular mechanism that they 
use to impart function.   
 








 The role of ceramide in apoptosis sparked our interest in the amphiphilic 
natural product.  One key finding is that the apoptotic activity of ceramide may be 
due to its ability to permeabilize lipid membranes.
6
  It is proposed that ceramides may 
induce apoptosis via self-assembly into large pores that span phospholipid 
membranes.
7
  This thesis, “Bioorganic Chemistry of Sphingolipids:  Pore Formation 
and Anion Transport” describes the discovery a of new ceramide analog that forms 
large pores in phospholipid membranes, as well as discovery that the natural product 
ceramide can facilitate the transmembrane transport of anions below pore forming 
concentrations. 
 
1.2 Thesis Organization 
 This thesis is organized into six chapters.  One initial goal of this work was to 
develop ceramide analogs that possess potential anti-tumor properties.  This work led 
to the discovery of a ceramide analog that is more active in forming pores in 
phospholipid membranes than natural ceramide.  Additionally, we have discovered 
that ceramide facilitates the transmembrane transport of anions under physiologically 
relevant conditions.   
 The discussion in Chapter 1 focuses on the bioorganic chemistry of various 
sphingolipids along the ceramide metabolic pathway.  Implications of ceramide in 
genetic diseases and apoptosis will be briefly discussed, as well as examples of 
synthetic ceramide mimics with interesting membrane properties.  The general 
introduction in Chapter 1 will be brief, as more tailored introductory portions 




increased membrane activity in terms of transmembrane pore formation.  Insights into 
the role of ceramides 1,3-diol in the self-assembly into channels will be discussed.  In 
Chapter 3, I discuss studies uncovering a new function for ceramide, at 
concentrations where transmembrane pores are not formed.  We have discovered that 
ceramide belongs to a very small group of natural products that facilitate the 
transmembrane transport of anions.  Chapter 4 focuses on the development of 
various compounds that function as transmembrane bicarbonate transporters.  
Chapter 5 describes future directions.  Finally, Chapter 6 contains the experimental 
protocols used for the research described in Chapters 2-4. 
 
1.3 Biosynthesis of Sphingosine and Ceramide 
 The formation of ceramide is catalyzed by membrane-bound enzymes in the 
endoplasmic reticulum.
8
  The first step in the biosynthesis of sphingolipids is the 
serine palmitoyltransferase catalyzed condensation of L-serine and palmitoyl-CoA 
(Figure 1.2).
9-11
  The resulting 3-ketosphinganine is stereoselectively reduced by 3-
ketosphinganine reductase to generate sphinganine, which is then acylated with a 
fatty acid chain by sphinganine N-acyl transferase to give dihydroceramide.  A trans 
double bond is then regioselectively introduced by dihydroceramide desaturase.  The 
resulting ceramides can be a mixture of analogs with varying chain lengths at the 
amide linkage.  While ceramides have been found in nature with N-acyl fatty acids 
ranging from 2 to 28 carbons in length, C16-ceramide 1 is the major species present 
in humans.
10,12
  Interestingly, sphingosine 3 is not directly produced from 









1.4 Sphingolipids and Disease 
 The sphingolipidoses are a group of inherited diseases that are included in the 
larger group of lysosomal storage diseases.
13,14
  Sphingolipidoses are caused by 
defects in genes that encode for proteins involved in the lysosomal degradation of 
sphingolipids.
15-17
  There are about 40 genetically different forms of lysosomal 
storage diseases known, of which at least 9 are due to the defective sphingolipid 
degradation (Table 1.1).
14,17
  Sphingolipidoses are characterized by the build-up of 
unmetabolized sphingolipids within cells.  For instance, Farber lipogranulomatosis 
(Farber disease) is caused by a deficiency of lysosomal ceramidase, and subsequent 
storage of unmetabolized C16-ceramide 1 in the lysosome.
18
  This causes C16-
ceramide 1 to build-up in the lungs, liver, skeletal muscle joints, and bones.
4
  The 
most common symptoms include progressive and painful joint deformations, 
problems breathing, and subcutaneous nodules called lipogranulomas.
19
  
Interestingly, the build-up of ceramide caused by Farber disease does not cause 













Table 1.1.  Diseases caused by misregulation of sphingolipids 
Disease Misregulated Sphingolipid Defective Protein Ref. 
Farber  C16-ceramide 1 Ceramidase 
18-20
 

























1.5 Ceramide Induced Apoptosis via Membrane Permeation 
 While ceramide and similar sphingolipids have implications in a variety of 
disease states, our interest in these sphingolipids stems from the ability of C16-
ceramide 1 and C2-ceramide 2 to induce apoptosis.  Studies have shown that 
endogenous ceramide levels increase in cells just before undergoing apoptosis.
44-46
  
Additionally, C16-ceramide 1 has been shown to cause membrane destabilization 
through leakage and fusion of vesicles.
6
  Aggregation and fusion of ceramide rich 
liposomes were detected as an increase in light scattering of the liposomal mixture.  
The cause of membrane destabilization remained unknown until Colombini and 
Siskind discovered that both C16-ceramide 1 and C2-ceramide 2 form large, stable 
channels in planar phospholipid membranes.
7




trace from electrophysiological planar membrane studies on C16-ceramide 1.  
Colombini observed specific opening and closing events in these studies that are 
characteristic of channel formation and subsequent collapse.  Interestingly, C16-
dihydroceramide, which lacks the trans double bond of C16-ceramide 1, shows no 
activity in this assay under the same conditions.  In fact, Colombini has also shown 
that C16-dihydroceramide actually interferes with the ability of C16-ceramide 1 to 
self-assemble into an active pore.
47
  This information suggests that the trans double 
bond of C16-ceramide 1 is structurally important for the formation of transmembrane 
channels, perhaps by providing some degree of conformational rigidity. 
 
Figure 1.3.  C16-ceramide 1 forms pores in planar phospholipid membranes.  Figure 
used with permission from reference 7. 
 
 Additionally, Colombini discovered that when C16-ceramide 1 and C2-
ceramide 2 were added to mitochondrial suspensions, they could induce the release of 
the apoptosis-inducing cytochrome c.
48
  These ceramide pores not only allowed the 
release of the 12 kDa cytochrome c, but also increased the permeability of the 
mitochondrial outer membrane to other small proteins with a molecular weight of less 
than 60 kDa.
49
  These studies suggest that ceramide self-assembly into pores in the 




the reason that C16-ceramide 1 induces apoptosis in natural systems.  A more detailed 
description of the putative transmembrane channels formed by C16-ceramide 1 can 
be found in Section 2.2 and 2.3 of this dissertation. 
 
1.6 Membrane-Active Synthetic Ceramide Analogs 
 There has been a large amount of work published on synthetic ceramide 
analogs that have been used to specifically investigate sphingolipid metabolism and 









provide excellent discussions on this subject.  For the purposes of this introductory 
chapter, I will focus on ceramide mimics and synthetic lipids that either form pores or 
facilitate the transport of ions across phospholipid membranes, or that are specifically 
shown to induce apoptosis, as this research is most pertinent to the research described 
in this dissertation. 
 
1.6.1 Gokel’s Ceramide Mimics  
 Research in the lab of George Gokel has produced a series of C16-ceramide 
mimics 4-7 that contain two lipophilic tails connected to a –OH containing headgroup 
via an amide linkage.
53
  Results from liposome assays suggest that compounds 5 and 





Figure 1.4  C16-ceramide mimics 4-7. 
 
 C16-ceramide mimics 4-7 were tested in chloride release assays using the 
chloride sensitive fluorescent dye lucigenin.  Liposomes were prepared containing 
lucigenin and KCl.  In the presence of Cl
-
, the fluorescence of lucigenin is quenched.  
Upon the transport of intravesicular Cl
-
 out of the liposome, an increase in lucigenin 
fluorescence is observed.  C16-ceramide mimics 4 and 6 were not active in this assay 
as they showed little activity above the baseline fluorescence.  Upon the addition of 
compounds 5, 7, or C16-ceramide 1, an increase in fluorescence was observed.  
Compound 5 was approximately as effective as C16-ceramide 1 at releasing chloride 





 Additionally, Gokel tested compounds 5-7 in a carboxyfluorescein release 
liposomal assay.  Carboxyfluorescein is a small organic dye with an approximate 
diameter of 10 Å that self-quenches at high concentrations.
54
  Liposomes were 
prepared containing carboxyfluorescein at self-quenching concentrations.  Upon the 
addition of compounds 5-7, an increase in fluorescence was observed corresponding 
to the carboxyfluorescein release, and subsequent dilution into the extravesicular 
buffer.  C16-ceramide mimic 7 was significantly more active in this assay than were 
compounds 5 and 6. 
 While it is clear from these experiments that Gokel’s C16-ceramide mimics 5 
and 7 do form pores in phospholipid membranes, there are some flaws in his 
interpretation of the results from the chloride transport assays.  He suggests that C16-
ceramide 1 and compounds 5 and 7 act as chloride transporters.  However, the 
concentration of compounds he used in these assays (15 mol%) was well above 
known ceramide pore forming concentrations (10 mol%).
3,55
  In this case, he is 
presumably observing chloride release due to large transmembrane pore formation, 
and not by anion specific transport.   
 
1.6.2 Bieberich’s Ceramide Mimic 
 Work in the Bieberich lab has shown that C16-serinol 7, a C16-ceramide 1 
mimic, induces apoptosis when added to cancerous neuroblastoma cells.
56
  
Structurally, C16-serinol 8 is similar to C16-ceramide 1 in that it contains a lipophilic 
tail attached to a polar headgroup via an amide linkage (Figure 1.5).  Additionally, 




contains two –OH groups.  The only major structural difference is the lack of a 
second hydrophobic tail that contains the trans double bond associated with the 
sphingolipid base. 
 
Figure 1.5.  Structural similarities between C16-ceramide 1 and C16-serinol 8. 
 
 While the Bieberich lab tested a variety of chain lengths ranging from C8- to 
C18-serinol, they found that C16-serinol 8, containing the same length tail as C16-
ceramide 1, was the most effective at inducing apoptosis in neuroblastoma cells.  
They found that addition of C16-serinol 8 to these cancerous cells caused an increase 
in endogenous C16-ceramide 1 levels.  Based on this information, they speculated 
that C16-serinol 8 induced apoptosis stems from the competitive inhibition of acid 
ceramidase, the enzyme that breaks down C16-ceramide 1 into sphingosine 3 (Figure 
1.2).  The build-up of endogenous C16-ceramide 1, either through signaling pathways 







1.6.3 Chanturiya’s Sphingomyelin Mimic 
 Sphingomyelin 9 is the phospholipid version of C16-ceramide 1.  It is 
produced endogenously from C16-ceramide 1 and sphingomyelin synthase.  
Misregulation of sphingomyelin has implications in the onset of Niemann-Pick 
disease (Table 1.1), as well as ulcerative colitis and atherosclerosis.
10,57
  Research 
from the lab of Chanturiya describes the development of a cationic sphingomeylin 




Figure 1.6.  Sphingomyelin 9 and a synthetic sphingomyelin mimic 10. 
 
 The membrane-active sphingomyelin mimic 10 reported by Chanturiya is a 
dimer of two sphingomyelin mimic units connected via a dodecyl acyl chain.  Each 
monomer possesses two –OH units, as well as two primary amines and two tertiary 




amines are presumably protonated yielding a cationic lipid.  When compound 10 was 
added to planar phospholipid membranes, discrete opening and closing events were 
observed.  Additionally, reverse potential experiments using sphingomyelin mimic 10 
suggested that the channels formed by this compound were selective for anions. 
 
1.6.4 Macchia and Danesi’s Lipophilic Nucleobase Ceramide Mimics 
 In an attempt to develop new and better apoptosis-inducing drugs, Macchia 
and Danesi developed an interesting example of a conformationally restrained C2-
ceramide 2 analog.
59
  In their studies, Macchia and Danesi replaced the polar 
headgroup region of ceramide with a uracil 11 or thiouracil 12 nucleobase. 
 
Figure 1.7.  C2-ceramide 2 analogs utilizing the nucleobases uracil 11 and thiouracil 
12 as the polar headgroup region. 
 
 These constrained analogs and C2-ceramide 2 were tested in their ability to 
inhibit cell growth in leukemia cells.  Compounds 11 and 12 proved to be 
significantly more active than C2-ceramide 2 in regards to inhibition of cell 
proliferation in the leukemia cell line tested.  The thiouracil analog 12 was the most 




ceramide 2 was the least active of the three, with an IC50 = 31.6 M.  Additionally, all 
three compounds were added to leukemia cells at concentrations (50 M) well above 
the IC50 values to test for the release of cytochrome c.  All three compounds induced 
cytochrome c release before the onset of apoptosis, with the thiouracil analog 12 
being the most active, and C2-ceramide 2 being the least active.  This is the first study 
to use lipophilic nucleobases as ceramide mimics.  While the polar headgroup is 
altered significantly in these analogs when compared to that of C2-ceramide 2, one 
could envision that the hydrogen-bonding motifs inherent in the uracil nucleobase 
may also assist in the self-assembly into transmembrane pores in a similar manner to 
that of ceramide. 
 
1.6.5 Smith’s Synthetic Lipid that Transports Anions via a Relay Mechanism 
 While not directly a ceramide mimic, Brad Smith and coworkers have 
developed a synthetic phospholipid with interesting membrane properties.
60
  They 
designed an anion transporter with an anion recognition unit (urea) attached at the end 
of one of the phospholipid acyl chains to give compound 13. 
 





 Smith and coworkers initially studied the ability of compound 13 to facilitate 
anion transport across phospholipid membranes.  Liposomes were prepared 
containing NO3
-
 and lucigenin, a Cl
-
 sensitive fluorescent dye.  Compound 13 was 
pre-incorporated into the phospholipid bilayer during liposome preparation.  Upon the 
addition of extravesicular Cl
-
, a decrease in fluorescence was observed corresponding 
to Cl
-
 influx into the liposomes.  However, when SO4
2-
 was used as the intravesicular 
anion, the rate of Cl
-
 influx was greatly reduced.  This is consistent with an anion 
exchange mechanism in that Cl
-
 influx only occurs with the concurrent efflux of 
another monovalent anion.  Sulfate anion is more hydrophilic and therefore not as 
easily transported as the singly charged chloride or nitrate anions.   
 Additionally, Smith proposed a relay mechanism as the method in which 
phospholipid 13 functions as an anion transport agent (Figure 1.9).  He gives two 
main arguments to support his proposed mechanism.  First, when compound 13 is not 
pre-incorporated into the liposomal membrane, no Cl
-
 transport was observed.  For 
anion transport to occur via the proposed relay mechanism, compound 13 is not of 
sufficient length to span the entire membrane, and must reside in both the inner and 
outer leaflets of the phospholipid bilayer in order for transport to occur.  Thus, 
without pre-incorporation, compound 13 could not equilibrate into both layers of the 
liposomal bilayer membrane within the experimental timeframe.  Smith suggests that 
this provides initial evidence for a relay mechanism such as depicted in Figure 1.9, as 
this mechanism requires compound 13 to reside in both the inner and outer leaflets of 
the phospholipid bilayer.   However, this result is not a particularly convincing 




explanation would be that when compound 13 was added to the external buffer 
containing the liposomes, it simply precipitated out of solution and therefore was 
never incorporated into the liposomes at all.  Another possible explanation is that 
compound 13 may aggregate with itself into some sort of micelle type structure when 
added to the extravesicular buffer.  In this case, insertion into the liposomal 
membrane could be slowed to the point that no activity was observed within the 
experimental timeframe. 
 
Figure 1.9.  Proposed anion transport relay mechanism for compound 13.  Figure 
used with permission from reference 60. 
 
 However, Smith offered a second, more convincing argument for his proposed 
relay mechanism.  For these experiments, liposomes were prepared using 
phospholipids of varying lengths.  Chloride transport by compound 13 decreased as 
bilayer thickness increased.  When the acyl carbon chain of the bilayer phospholipids 
was increased from 14 to 18, a sharp decrease in anion transport was observed.  No 
transport was observed when the bilayer phospholipid chain length was above 18.  
Since compound 13 has an acyl chain length of 15, Smith concluded that it was not 
long enough to span each leaflet of the bilayer according to the proposed relay 




recognition units within each bilayer leaflet, thus shutting down the relay of Cl
-
 from 
13 in one leaflet to another molecule of 13 on the other leaflet. 
 
1.7 Summary 
 Ceramide is an amphiphilic natural product with implications in multiple 
disease states and cellular processes, including apoptosis.  Ceramides role in 
apoptosis may arise from its ability to permeabilize membranes.  One possible way in 
which ceramide induces apoptosis is through self-assembly into large pores in the 
mitochondrial outer membrane.  Pores formed by ceramide are large enough to 
release the apoptosis-inducing cytochrome c.  A number of ceramide mimics have 
been developed in order to take advantage of the membrane properties of this unique 
amphiphile.  In this thesis, I will discuss a new ceramide analog that is more active 
than naturally occurring ceramide in terms of forming large pores in phospholipid 
membranes.  Additionally, I will describe a newly discovered function of ceramide 












Chapter 2 : C2-Ceramide Diacetate Forms Large Pores in 
Phospholipid Membranes 
 
Some of the experimental work described in this chapter was performed in 
collaboration with Dr. Marco Colombini in the Department of Biology at the 
University of Maryland.  Dr. Peter Y. Zavalij determined the crystal structure of C2-
pmb 15 that is described in this chapter. 
 
2.1 Introduction 
 One original goal of the research described in this dissertation was the 
preparation and development of ceramide analogs that possess potential anti-tumor 
properties.  Ceramide 1 is known to play important roles in the regulation of multiple 
cellular processes, including cytosolic protein phosphatase activation, cell 
differentiation and apoptosis.1-3,61,62  Using pH sensitive modifications to the 
ceramide head group, we hoped to render ceramide “inactive” until it reached the 
target cell or organelle.  This work also explores the role of the 1,3-diol unit in the 
self-assembly of ceramide into membrane-active structures using protected ceramide 







2.2 Ceramide Pores Allow the Release of Apoptosis-Inducing Cytochrome C 
 In 1976, Pascher indicated that ceramides may perturb membrane 
permeability.
63
  Based on solid state structures of C16-ceramide 1, he suggested that 
ceramide may increase permeability of membranes if the head group hydroxyls 
participated in hydrogen bonding with water molecules.  Pascher postulated that this 
could destabilize the membrane by either slightly pulling ceramide molecules away 
from the membrane layer, or by increasing the molecular area at the membrane 




observed by Huang and coworkers.
64
  Using 
2
H NMR and deuterated liposomes, 
Huang observed that ceramide induces lateral phase separation of the bilayers into 
liquid crystalline phases and ceramide-rich gel phases.  More recently, Johnston and 
coworkers observed these ceramide-rich domains on lipid monolayers using atomic 
force microscopy.
65
  Johnston found that the edges of these ceramide-rich domains 
are raised above the surrounding monolayer by ~1 nm.   
 Ceramide has also been shown to cause membrane destabilization through 
leakage and fusion of vesicles.
6
  Aggregation and fusion of ceramide rich liposomes 
were detected as an increase in light scattering of the liposomal mixture.  The cause 
of membrane destabilization remained unknown until Colombini and Siskind 
discovered that both C16-ceramide 1 and C2-ceramide 2 form large, stable channels 
in planar phospholipid membranes.
7
  When added to mitochondrial suspensions, 
ceramide has been shown to induce the release of apoptosis-inducing cytochrome c.
48
  
The ceramide pores not only allowed the release of the 12 kDa cytochrome c, but 
increased the permeability of the mitochondrial outer membrane to other small 
proteins that had a molecular weight of less than 60 kDa.
49





Figure 2.1.  Molecular dynamics simulation of a C16-ceramide 1 nanopore.  Figure 
used with permission from reference 66.   
 
2.3 The Role of Ceramides 1,3-Diol Unit in Pore Formation 
 Although it is known that ceramide forms large pores in phospholipid 
membranes, the actual self-assembled structure of the pore is still unknown.  While 
there is little experimental evidence available, molecular dynamics simulations by 
Columbini, Sukharev and colleagues suggest a possible membrane-active structure.
66
  
They propose that barrel-rosette type channels are formed by self-assembly of 
multiple ceramide subunits, and that these structures are stabilized by hydrogen bonds 
(Figure 2.1).  A closer look at the structure of the putative pore reveals that the 
internal wall of the pore may be composed of a hydrogen bonding array involving the 
1,3-diol unit of ceramide (Figure 2.2a).  This suggests that the 1,3-diol functionality 




these self-assembled pores was proposed to be found in a column of hydrogen bonds 
between the carbonyl oxygen and the –NH of neighboring amides (Figure 2.2b) 
 
Figure 2.2.  a) Hydrogen bonding of the 1,3-diol unit of C16-ceramide 1 helps form 
the inner wall of the pore. b) Vertical columns of ceramides held together by amide 
hydrogen bonding.  Figure used with permission from reference 66. 
 
2.4 Protected Ceramide Analogs as Potential Pro-Drugs 
 One original goal of this project was to prepare C16-ceramide 1 analogs with 
pH sensitive protecting groups that masked the 1,3-diol unit for potential use as anti-
tumor agents.  Additionally, these analogs with protected diols could be used to study 
the role of ceramide’s 1,3-diol unit in the self-assembly and stabilization of 
transmembrane pores.  By protecting the 1,3-diol of C16-ceramide 1, we hoped to 
render the compound inactive in terms of its ability to self-assemble into functional 
pores.  Upon deprotection, active ceramide would then be free to self-assemble into 





Scheme 2.1.  General strategy for the development of ceramide pro-drugs. 
 
 There are many different strategies being developed to deliver drugs to 
cancerous cells.  These drug delivery vehicles include carbon nanotubes, gold 
nanoparticles, and liposomes.
67-69
  The one thing these all have in common is that the 
drug delivery vehicles are ingested into the target cell via endocytosis.  In the final 
phase of endocytosis, lysosomes engulf the drug and fuse with the phospholipid 
membrane of the cell, releasing the contents of the lysosome into the cell.
70
  With a 
pH ~5, the lysosome is relatively acidic when compared to physiological pH (7.4).  In 
fact, folate-conjugated polymer micelles have recently been developed with this in 
mind.
71
  These micelles have increased drug release rates at pH 5.  This is why acid 
labile protecting groups were originally chosen to block the 1,3-diol unit of ceramide.  
Upon ingestion by the lysosome, we reasoned that deprotection could produce active 






2.5 Preparation of a p-Methoxybenzylidene C16-Ceramide Analog 
 In order to block the 1,3-diol unit of C16-ceramide 1, we first chose to use 
acid-labile acetal protecting groups.  Starting with C16-ceramide 1, p-
methoxybenzylidene C16-ceramide (C16-pmb 14) was prepared in one step.  Thus, 
C16-ceramide 1 was reacted with p-anisaldehyde in the presence of a Lewis acid 
catalyst, ZnCl2, giving C16-pmb 14 in 80% yield following purification (Scheme 
2.2).  The 
1
H NMR spectrum of C16-pmb 14 in CDCl3 shows the appearance of the 
aromatic protons and the –CH3 of the p-methoxybenzylidene protecting group, as 
well as the loss of the –OH groups and an upfield shift approximately  1.30 ppm of 
the amide –NH proton (Figure 2.3).  This upfield shift is presumably due to a 
disruption of intramolecular hydrogen bonding between the amide –NH and the 










Figure 2.3.  
1
H NMR spectrum of C16-pmb 14 in CDCl3.  
 
2.6 Mitochondrial Permeabilization Assay 
 In order to determine if protecting the 1,3-diol unit of C16-ceramide 1 with a 
p-methoxybenzylidene acetal would render it inactive, C16-pmb 14 was subjected to 
mitochondrial permeabilization assays.
47,49
  These experiments were done in 
collaboration with Meenu Perera, Kevin Yang and Dr. Marco Colombini in the 
Department of Biology at the University of Maryland.  Purified rat liver mitochondria 
suspensions were incubated with either C16-ceramide 1 or C16-pmb 14.  Reduced 
cytochrome c was then added to the mitochondria/ceramide solution.  If pores are 
formed that are large enough to allow the reduced cytochrome c to enter the 
mitochondria, then the reduced protein becomes oxidized by the cytochrome c 




cytochrome c is monitored as a decrease in absorbance of the reduced cytochrome c 
at 550 nm. 
 Figure 2.4 compares the ability of C16-ceramide 1 and the protected 
derivative, C16-pmb 14 to permeabilize mitochondrial membranes to cytochrome c.  
C16-ceramide 1 allowed cytochrome c to cross the mitochondrial outer membrane, 
while C16-pmb 14 alone showed significantly less activity in this assay.  This 
suggests that the 1,3-diol unit plays an important role in C16-ceramide 1 self-
assembling into a transmembrane pore.  Interestingly, when a 1:1 equimolar mixture 
of the two compounds were added to mitochondrial suspensions, the rate of 
cytochrome c oxidation was close to that of C16-ceramide 1 alone.  This last result 
suggests that C16-ceramide 1 and C16-pmb 14 may work in a cooperative manner in 
order to form membrane-active structures.  This result was encouraging with regards 
to using C16-pmb 14 as a potential anti-tumor pro-drug in that only a small amount of 
the acetal analog may need to be deprotected in order to induce the release of 
cytochrome c from the mitochondria. 
 





 While these initial results were encouraging, liposome assays were unable to 
be carried out using these C16 chain compounds due to solubility issues in many 
common solvents, including DMSO.  In order to develop compounds that were easier 
to work with, analogs were prepared using the short-chain C2-ceramide 2.  Indeed, 
these short-chain analogs displayed much better solubility in a variety of solvents. 
 
2.7 Preparation of C2-Ceramide 2 Analogs 
 In order to prepare ceramide analogs that are soluble in DMSO, C2-ceramide 
2 was used as the starting material.  Using the same preparation as described above 
for the C16-pmb 14 analog, the p-methoxybenzylidene C2-ceramide (C2-pmb 15) 
was made in 67 % yield after purification.  The X-ray structure for crystals of C2-
pmb 15 grown from DMSO can be seen in Figure 2.5.  Hydrogen bonds are observed 
between the –NH of one molecule of C2-pmb 15 with the carbonyl oxygen of an 
adjacent molecule.  This solid state evidence of amide hydrogen bonding supports the 
idea from molecular dynamics simulations by Colombini and Sukharev (Figure 2.2b) 
that columns of hydrogen bonded amides may stabilize the membrane-active structure 
of ceramide pores.
66






Figure 2.5.  Crystal structure of C2-pmb 15.   
 
 Additionally, a 1,3-diacetyl C2-ceramide (C2-diacetate 16) analog was 
prepared as a possible base/esterase sensitive protected ceramide.  Shayman and 
colleagues have found an enzyme that catalyzes the esterification of short chain 
ceramides.
72
  They discovered a unique transacylase enzyme found in canine and 
mouse cells that esterifies C2-ceramide 2 to form 1-O-acetylceramide.  While there 
are no studies, to our knowledge, that specifically discuss hydrolysis of O-acylated 
ceramides, it is reasonable to believe that enzymes exist that may carry out this task.  
Thus, acetyl chloride was slowly added to a solution of C2-ceramide 2 and 
triethylamine in CH2Cl2 to give C2 diacetate 16 in 70 % yield after workup and 
purification (Scheme 2.3).  Additionally, in a previous crystal structure study of C2-










Scheme 2.3.  Preparation of C2-diacetate 16. 
 
2.8 Carboxyfluorescein (CF) Release Assay for Pore Formation 
 One purpose of these studies was to determine what role the 1,3-diol unit of 
ceramide may have in pore formation within phospholipid bilayers.  Based on the 
Colombini and Sukharev molecular dynamics studies,
66
 we reasoned that the 
ceramide analogs C2-pmb 15 and C2-diacetate 16 would be rendered inactive with 





Scheme 2.4.  CF release assay 
 
 In order to determine if these ceramide analogs form large pores in 
phospholipid membranes, we decided to test these analogs in carboxyfluorescein (CF) 









 to test for compounds that form large 
pores in phospholipid membranes.  Liposomes were prepared containing CF, a 
fluorescent dye (Scheme 2.4).  Additionally, a fluorescence quenching agent, p-
zylene-bis-pyridinium bromide (DPX), was encapsulated in the vesicles along with 
the CF.  In the presence of DPX, CF fluorescence is quenched.  If any of these 
ceramide analogs form pores that are large enough to allow the release of the 
intravesicular CF and/or DPX, an increase in fluorescence should be observed.  Pores 
observed in these CF release assays are generally thought to have an internal pore 






 C2-ceramide 2, C2-pmb 15, and C2-diacetate 16 were all tested in this CF 
release assay.  When added at a 15 mol% C2-ceramide 2 to lipid ratio, an increase in 
CF fluorescence was observed (Figure 2.6).  As expected, C2-pmb 15, with the 1.3-
diol unit blocked, showed a significant decrease in pore-forming activity when 
compared to that of C2-ceramide 2.  This is consistent with the cytochrome c 
mitochondrial release assays performed using the longer chain C16-pmb 15 analog. 
 
Figure 2.6.  CF release assay comparing C2-ceramide 2 and C2-pmb 15. 
 
 C2-diacetate 16 was also tested in the CF release assay.  This analog has the 
two hydroxyls of the 1,3-diol blocked, but is less conformationally restricted than the 
acetal analog C2-pmb 15.   To our surprise, a large increase in the CF release activity 
of the C2-diacetate 16 was observed when compared to that of the natural C2-
ceramide 2 (Figure 2.7).  These experiments suggest that C2-diacetate 16 readily 
forms pores that are large enough to allow the release of the 10 Å wide CF from 
liposomes.  While these results are unexpected, they do not prove that the pores 






Figure 2.7.  CF release assay comparing C2-ceramide 2 and C2-diacetate 16. 
 
2.9 Pore Sizing using FITC-Dextrans 
 In an attempt to determine the relative size of the pores formed by C2-
diacetate 16, fluorescent isothiocyanate dextrans (FITC-dextrans) were used as an 
intravesicular fluorescent probe in liposome experiments.  FITC-dextrans are 
composed of fluorescein derivatives attached to dextran polymers of various sizes 
(Figure 2.8a).  FITC-dextrans have been previously used in materials research to 
determine the relative pore size in microporous films.
76,77
  Biological applications 
include the use of FITC-dextrans as fluorescent probes to measure large molecule 
flux across epithelial and hepatoma cells.
78-80
  In 1986, Stutzin developed a 
fluorescence assay using FITC-dextrans to monitor the synexin-induced fusion of 
bovine chromaffin granule ghosts.
81
  More recently, FITC-dextrans have been used in 








Figure 2.8.  a) General structure of a FITC-dextran. b) Size-exclusion 
chromatography showing the sizes of FD4 and FD10 relative to cytochrome c.  Figure 
used with permission from reference 83. 
 
 Ceramide is known to form large pores in the mitochondrial outer membrane; 
pores that are large enough to allow the release of the apoptosis-inducing cytochrome 
c.
48
  In order to determine if pores formed by C2-diacetate 16 are large enough to 
release proteins as large as cytochrome c, and therefore, potentially induce apoptosis, 
liposomes were prepared containing FITC-dextrans.  Commercially available FITC-
dextrans range in size from FD4 (4 kDa) to FD150 (150 kDa).
84
  For these 
experiments, FD10 (10 kDa) was chosen because its Stokes radius of 33 Å is larger 
than that of cytochrome c (17 Å).
84,85
  Additionally, size exclusion chromatography 
performed by Sandoval and coworkers determined that the relative hydrodynamic 
radius of cytochrome c falls between that of dextrans FD4 and FD10 (Figure 2.8b).
83
  
Therefore, if C2-diacetate 16 can form pores large enough to release FD10 from 
phospholipid liposomes, it is reasonable to believe that these pores should also be 






Scheme 2.5.  FITC-dextran (FD10) release assay. 
 
 EYPC liposomes were prepared in a HEPES buffer containing 7.5 mM of the 
dextran dye FD10.  At these concentrations, the FITC-dextran is moderately self-
quenched (Scheme 2.5).
83
  The amount of self-quenching for FD10 is significantly 
less than that of CF, due to the increased steric bulk surrounding the fluorophore.  If 
pores are formed in the phospholipid membrane that are large enough to release this 
10 kDa FITC-dextran, then an increase in fluorescence should be observed.  Upon the 
addition of C2-ceramide 2, C2-pmb 15, and C2-diacetate 16, we observed 
fluorescence responses that were remarkably similar to that of previous experiments 
using the smaller CF dye (Figure 2.9).  Thus, the acetal C2-pmb 15 gave little 
response above the DMSO baseline, while the C2-diacetate 16 gives a much larger 







Figure 2.9.  FITC-dextran release assay results comparing C2-ceramide 2, C2-pmb 
15, and C2-diacetate 16. 
 
2.10 Mitochondrial Permeabilization Assay using C2-Diacetate 16 
 With the knowledge that C2-diacetate 16 forms pores that should be large 
enough to allow cytochrome c to pass through a phospholipid bilayer, this compound 
was tested in the mitochondrial permeabilization assay (Figure 2.10).  Unlike the 
previous mitochondrial studies with the C16-pmb 14 (Figure 2.4), C2-diacetate 16 
does retain activity in this assay when compared to C2-ceramide 2.  This assay 
supports the results from the FITC-dextran release assay in that C2-diacetate 16 does 
increase the permeability of the mitochondrial outer membrane to small proteins such 










 In this chapter, we studied the role of the 1,3-diol unit in the self-assembly of 
ceramide pores using alcohol protecting groups.  As expected, blocking the 1,3-diol 
unit with a p-methoxybenzylidene group greatly diminished the ability of C16-
ceramide 1 and C2-ceramide 2 to form pores in phospholipid bilayers.   To our 
surprise, the C2-diacetate 16 analog seems to be more active in liposomal dye release 
assays than that of natural C2-ceramide 2.  These results seemingly go against 
previous hypotheses suggesting that the hydrogen bonding of the ceramide headgroup 
is an important factor in self-assembly into membrane-active structures.  However, a 
closer look at the structure of C2-diacetate 16 allows for a possible explanation of 
these results.   
 Ceramides located in the stratum corneum layer of the skin are thought to play 






Additionally, the deficiency of skin ceramides is linked to various skin diseases 
ranging from dermatitis and psoriasis, as well as Gaucher and Niemann-Pick 
Diseases.
4
  Based on the fact that ceramides play important roles in water regulation 
in the skin, we speculate that water may well play an important role in stabilization of 
ceramide pores in phospholipid membranes.   
 Protection of the alcohols of ceramide with ester groups removes two possible 
hydrogen bond donors from the ceramide headgroup.  However, this protection 
strategy adds two additional hydrogen bond acceptors in the carbonyl oxygen of the 
ester functionality.  Additionally, any pore formed in a phospholipid bilayer would be 
filled with water.  We currently speculate that hydrogen bonding in the ceramide 
headgroup is integral to pore self-assembly, and that formation of these membrane-
active structures may be a cooperative event also involving hydrogen bound water 
molecules.  In the case of C2-diacetate 16, the partially positive hydrogens of water 
might well help stabilize the pore structure by hydrogen bonding with the additional 
hydrogen bond acceptors introduced in the ceramide headgroup. 
 





2.12 Future Directions 
 Further experiments are necessary to explore the role of water in the self-
assembly of C2-ceramide 2 and C2-diacetate 16 into membrane active structures.  
Molecular dynamics simulations of these compounds including water molecules 
could give insight into the role of hydrogen bound water in the stabilization of 
ceramide pores.   
 In terms of accomplishing the original goals of this project in the development 
of anti-tumor pro-drugs, additional blocked analogs are needed.  Preliminary results 
suggest that the use of acetals in blocking the 1,3-diol unit renders ceramide unable to 
form large pores in phospholipid bilayers.  Unfortunately, the C2-pmb 15 analog 
discussed is likely equipped with a protecting group that is not labile at lysosomal pH 
of 5 (Green’s book ”Protective Groups in Organic Synthesis” suggests p-
methoxybenzylidene acetals are highly labile at pH < 4).
89
  However, the preparation 
of a cyclic ortho ester protected analog should create an inactive analog that is labile 
at mildly acidic pHs.   Cyclic ortho esters are readily cleaved by acidic hydrolysis in 











Chapter 3 : C2-Ceramide Facilitates Anion Exchange across 
Phospholipid Bilayers 
 
Portions of this chapter have been published in reference 91. 
 Harrell, W. A., Jr.; Bergmeyer, M. L.; Zavalij, P. Y.; Davis, J. T. Ceramide-
Mediated Transport of Chloride and Bicarbonate Across Phospholipid 
Membranes. Chem. Commun. 2010, 46, 3950–3952. 
Some of the experimental work described in this chapter was performed by Ms. Liesel 
M. Bergmeyer, an undergraduate HHMI fellow working under my supervision.  Dr. 
Peter Y. Zavalij determined the crystal structure of isopropylidene C2-ceramide 18 
that is described in this chapter. 
 
3.1 Introduction 
 The goals of the research in this chapter are two-fold:  1) to investigate the 
anion transport properties of C2-ceramide 2; and 2) to prepare analogs of C2-
ceramide that might have increased transport activities.  These studies are based on 
the fact that C2-ceramide 2 self-assembles at concentrations >10 mol% within 
phospholipid membranes to form large pores.
55
  However, to our knowledge, no 
studies exist that have investigated the membrane properties of ceramide at lower 
concentrations.  The major finding in this chapter is the discovery that C2-ceramide 2 
transports chloride anions across phospholipid membranes at concentrations that are 
below known pore forming concentrations.  Before describing the new studies on C2-




background on natural products that are known anion transporters.  I will also provide 






3.2 Small Molecule Natural Products that Transport Anions 
 Numerous natural products facilitate translocation of cations across 
phospholipid membranes.  For example, valinomycin and gramicidin A are probably 
the best known small molecule natural products that transport cations.
92,93





 A. P. Davis, Sheppard and Smith,
96
 and by J. T. Davis 
and Quesada
97
 provide excellent discussions on the large field of synthetic anion 
transporters.  However, there are very few small molecule natural products that are 













implicated in the transmembrane transport of anions, with the prodigiosin and 
amphotericin B being the most studied.   
 
3.2.1 Duramycin 
 Channel-forming peptides have been studied extensively due to their 
antibiotic properties, with the cation-selective gramicidin being the most studied.
92
  
However, examples of peptides that function as anion selective transporters are much 
more rare.  The natural product duramycin 20 is a nonadecapeptide antibiotic isolated 
from Streptoverticillium cinnamomeus.
102
  Planar membrane studies show that 
duramycin 20 forms anion selective channels that transport Cl
-
 across phospholipid 
membranes.
98
  The authors postulate that multiple molecules of duramycin 20 self-
assemble in the lipid bilayer to form the membrane active structure.  
 





 Additionally, duramycin 20 has been found to enhance chloride secretion in 
airway epthilium.
103
  These discoveries have lead to duramycin 20 being tested in 
clinical trials for treatment of cystic fibrosis,
104
 a disease caused by defects in the 
cystic fibrosis transmembrane regulator (CFTR), a protein that facilitates the 









 Prodigiosin 21, first isolated in its pure form in 1929, is a heterocyclic natural 
product that has a bright red color.
109
  However, its structure was only fully elucidated 




 synthesis.  Prodigiosins have 
been shown to possess potent antimicrobial, anticancer, and immunosuppressive 
activities.
112,113
  In 1995, Kataoka and colleagues showed that prodigiosin 21 
inhibited the activity of V-ATPase, an enzyme responsible for active transport of 
protons across intracellular membranes in certain cellular organelles, such as 
lysosomes and the Golgi apparatus.
114,115
  However, these papers did not discuss a 
specific mechanism for how prodigiosin disrupts the proton pump of V-ATPase. 
 





 In 1998, Ohkuma, Wasserman and colleagues discovered that prodigiosins 







  In the presence of HCl, the weakly basic prodigiosin 21 (pKa ~ 7) 
becomes protonated, forming a binding pocket for the residual Cl
-
 anion to bind 
(Figure 3.2).  In liposomal solutions containing an excess of extravesicular Cl
-
, they 
found that the internal pH dropped with the addition of prodigiosin 21, corresponding 




 to the interior of the liposome. 
 However, a later study by Seganish and Davis showed that anion transport by 
prodigiosin 21 does not always occur through a symport mechanism.  The authors 
determined that prodigiosin 21 could also facilitate anion transport through an anion 
exchange (antiport) mechanism.
119
  Liposomes were prepared containing either 
Na2SO4 or NaNO3 with external NaCl.  They monitored both the internal pH of the 
liposomes and Cl
-
 influx using pyranine and lucigenin dyes, respectively.  Addition of 
prodigiosin 21 to the sulfate containing liposomes resulted in immediate acidification 
inside the liposome with very little concomitant Cl
-
 influx.  In this case, these results 









 antiport).  However, addition of prodigiosin 21 




, with no 
internal pH change.  This study was significant because it demonstrated that 
prodigiosin 21 can facilitate the transmembrane transport of anions via differing 






3.2.3 Amphotericin B 
 Amphotericin B (AmB 22) is an antifungal antibiotic that is used for the 
treatment of systemic fungal infections.
120
  Early work on AmB 22 suggests that its 
mechanism of action is the generation of ion channels containing 4-12 individual 
molecules that self-assemble in the membrane of the target cell.
121-123
  These channels 
are known to allow potassium ions and small organic molecules to cross through the 
phospholipid bilayers.
124,125
    
 However, recent study planar membrane by Asandei and Luchian discovered 
some interesting anion transport properties of AmB 22.
100
  Reverse potential planar 
membrane studies of AmB 22 at pH 7.07 and 11.0 gave positive values of 8.3  0.2 
mV and 28.1  2.4 mV, respectively, corresponding to increasing cation (K
+
) 
selectivity as the pH of the solution becomes more basic.  However, at pH 2.82, AmB 
22 gave a negative potential of -20.9  0.7 mV, corresponding to a strong anion 
selectivity (Cl
-
 in this case).  This discovery is unique in that the natural product AmB 
22 can act as a pH tunable ion channel.   
 
Figure 3.3.  a) The structure of AmB 22.  b)  Results from reverse potential planar 
membrane studies of AmB 22 at pH = 2 showing a negative potential, corresponding 





 Molecular dynamics simulations of AmB 22 channels reveal that –OH groups 
line the inner wall of the membrane active structure (Figure 3.4).
124-126
  This suggests 
that the –OH groups (red) play a vital role in shuttling anions (or cations) across 
phospholipid membranes.  Anion selectivity at low pH is thought to arise from 
“gating” due to the protonated amines (blue) capping the structure, preventing cations 




Figure 3.4.  Molecular dynamics simulation of self-assembled AmB 22 channel.  
Figure used with permission from reference 124. 
 
3.2.4 Pamamycin-607 
 Pamamycin-607 23 is a 18-membered macrolide that was originally isolated 
from Streptomyces alboniger in 1987 by Marumo and co-workers.
127
  Pamamycin-
607 23 has been of particular interest for its potent activity against the gram-positive 
bacteria Mycobacterium turberculosis.
128
  Pamamycin-607 23 has been suggested to 
have supposedly have anionophoric properties,
101,129,130




footnote of review articles as a natural product anion transporter.
96
  However, to our 
knowledge there is absolutely no report in the literature to back up this claim.  In fact, 
the anionophoric properties of pamamycin-607 23 are suspect, at best.  The structure 
in Figure 3.5 of Pamamycin-607 23 reveals that it actually has more in common with 





Figure 3.5.  Structure of pamamycin-607 23 and an example of a pamamycin-607 23 
lipophilic anion pair with KMnO4. 
 
 Pamamycin-607 23 can bind and transport anionic species from aqueous 
layers to organic layers through the formation of lipophilic ion pairs.
130
  Grafe and 
colleagues were able to use pamamycin-607 23 to transport methylorange, a small 
anionic dye, from a water layer into a toluene layer.
133
  Additionally, Marumo and co-
workers determined that pamamycin-607 23 selectively transports anions over cations 
from aqueous phases to organic layers at neutral and acidic conditons.
129
  When 
KMnO4 was partitioned between a water layer and a pamamycin-607 23 containing 
benzene layer, only MnO4
-
 was transferred to the benzene layer, while K
+
 remained in 
the aqueous layer (presumably bound to pamamycin-607 23).   
 These studies only present evidence that pamamycin-607 23 can act as a phase 




to crown ethers in this regard.  In my opinion, these studies show that pamamycin-
607 23 no more of an anionophore than the crown ethers.  The “binding” of an anion 
is a secondary electrostatic event that follows the binding of a cation in the 
pamamycin-607 23 crown ether like binding pocket.   
 
3.3 Synthetic Anion Transporters that Utilize O-H····A
-
 Interactions 
 While most anion-binding ligands use amide –NH groups to coordinate 
anions,
94,134,135 
there are a growing number of receptors that use –OH groups for anion 
recognition.
136-140
  Furthermore, crystal structures of anion binding proteins often 
show OH side-chains as integral to the active site.
141-143
  For instance, Luecke and 
Quiocho discovered that a phosphate buried within the binding pocket of the 
phosphate-binding protein is held in place by 12 hydrogen-bonds, four of which are –
OH groups from two serines and two threonines.
141
   
 MacKinnon and colleagues were able to obtain a crystal structure for the ClC 
chloride channel protein from S. typhimurium.
143
  These studies showed that chloride 
selectivity is accomplished in the narrowest portion of the channel, the so-called ion 
filter.  In this region (depicted in Figure 3.6), chloride is selectively coordinated to 
multiple hydrogen bond donors, including two –OH groups, one from a serine and 










 In another study by Quiocho, the crystal structure of the sulfate-binding 
protein of Salmonella typhimurium shows a serine within the binding pocket.
144
  Site-
directed mutagenesis that changed the serine to a cysteine residue caused a 3200-fold 
decrease in sulfate binding activity.
142
  These three crystal structure studies suggest 
that –OH containing amino acids play integral roles in the binding and transport of 
anions in natural systems. 
 
3.3.1 Matile’s Rigid-Rod Polyol 24 Forms Ion Channels 
 While natural products like AmB 22 take advantage of –OH functionalities to 
bind and transport anions, the vast majority of synthetic anion receptors utilize only   
–NH groups as hydrogen bond donors.
94,134,135
  Using this natural product as 
inspiration, researchers in the lab of Stefan Matile used synthesized an AmB 22 
mimic, consisting of eight 1,2-diol functionalities appended to a rigid aromatic 
backbone.
145





Figure 3.7.  Matile’s rigid polyol 24, an AmB 22 mimic. 
 
 Like AmB 22, Matile’s rigid polyol 24 transports different ions under 
different conditions.  Polyol 24 was found to be generally selective for H
+
 and other 
cations over anions.  However, when HPTS and chloride containing liposomes were 
subjected to an external pH change, Matile and coworkers observed an increase in 




 exchange.  They also proposed that polyol 
24, which has a length of approximately 34 Å, could span the membrane and act as an 
ion channel by moving anions (or cations) across phospholipid membranes through a 
hydrogen-bond chain mechanism.  In this case, anions (or cations) would effectively 
hop from one “binding site” to another until it crossed the lipid bilayer.  However, a 
later voltage-clamp study by the Matile group with polyol 24 gave conductances too 
large for the ion channel to be comprised of just one unit.
146
  They proposed that the 
membrane-active structure was comprised of four self-assembled polyol 24 subunits. 
  
3.3.2 Catechols as Anion Transporters 
 Catechols have been well studied in the lab of D. K. Smith as receptors for 
chloride.
139,147,148
  Additionally, Miyaji and Sessler found that dyes containing 
catechols functionalities can be used as colorimetric anion sensors.
149




recently have catechols been used to facilitate the transmembrane transport of anions.  
Berezin and Davis developed a bis-catechol 25 receptor that binds and transports 
anions.
150
  The authors appended two catechols to a tren scaffold.  A lipophilic carbon 
tail was attached to the third arm of the tren scaffold in order to help the bis-catechol 
25 partition into a phospholipid membrane.  Using bis-catechol 25, Berezin and Davis 













.  Additionally, when the hydrogen-bond donor groups 
were blocked (26), no anion transport was observed.  This suggests that the –OH 
groups of the catechols functionality play a vital role in these compounds ability to 
transport anions across phospholipid membranes.  
 
 
Figure 3.8.  Bis-catechol 25 facilitates the transmembrane transport of anions, while 









3.4 Anion Binding Studies of C2-ceramide 
 In this study we compared the anion binding and anion transport properties of 
C2-ceramide 2 and its 1,3-isopropylidene protected derivative 18.
91
  These 
compounds were compared because we wanted to discern the role of ceramide’s 1,3-
diol in anion recognition and transport. 
 
3.4.1 The C2-Ceramide Tridentate Anion Binding Motif 
 In this study, we sought to identify membrane-active natural products that 
might use –OH groups for transporting anions.  Our attention turned to the ceramides.  
We reasoned that the 1,3-diol and neighboring amide –NH functionalities in C2-
ceramide 2 might provide an effective tridentate motif for binding anions (Figure 
3.9).  Our rationale was bolstered by reports that ceramides give robust signals for Cl
-
 





Figure 3.9.  Model showing the binding of Cl
-







3.4.2 Preparation and Characterization of Isopropylidene C2-Ceramide 18 
 In order to determine the role of the 1,3-diol unit in the ability of C2-ceramide 
2 to bind anions, isopropylidene C2-ceramide 18 was prepared in one step.  C2-
ceramide 2 was reacted with 2,2-dimethoxypropane in the presence of an acid 
catalyst, giving isopropylidene C2-ceramide 18 in 94 % yield (Scheme 3.1).  The 
1
H 
NMR spectrum of isopropylidene C2-ceramide 18 shows the loss of the –OH protons 
of ceramide, as well as an upfield shift of the –NH proton (Figure 3.10).  
Additionally, the NMR also shows the clear presence of the diastereotopic methyl 
groups of the newly formed isopropylidene group.  To our knowledge, this is the first 
literature example of the preparation of isopropylidene C2-ceramide 18. 
 






Figure 3.10.  
1
H NMR spectrum (in CDCl3) of isopropylidene C2-ceramide 18 
distinguished by the loss of the broad –OH signals at 2.5 ppm and the appearance of 
protons 9 and 10 of the isopropylidene functionality.  Additionally, a 1 ppm upfield 
shift of the –NH proton is observed when compared to C2-ceramide 2.  
 
 Additionally, we were able to obtain an X-ray crystal structure for 
isopropylidene C2-ceramide 18.  Interestingly, four symmetrically independent 
molecules make up the unit cell.  While the –OH groups in this analog are blocked 
from participating as hydrogen bond donors, hydrogen-bonding is observed between 







Figure 3.11.  Depiction of the crystal structure of isopropylidene C2-ceramide 18.  
The ends of the lipophilic tails have been removed for clarity.   
 
3.4.3 ESI-MS Evidence that C2-Ceramide 2 Binds Anions 
 We initially obtained evidence for anion binding by C2-ceramide 2 from mass 
spectrometry (Figure 3.12).  Previous mass spectrometry studies on longer chain 





  ESI-MS analysis in negative mode of a solution of C2-ceramide 2 and 
tetrabutylammonium chloride (TBACl) in CH2Cl2 showed a strong signal for the 
adduct at m/z = 376.21 (ESI-MS [M+Cl]
-
 calculated for C20H39ClNO3
-
, m/z = 
376.26).  Isopropylidene C2-ceramide 18, which lacks the 1,3-diol, did not form any 
such detectable Cl
-
 adduct under identical conditions (ESI-MS [M+Cl]
-
 calculated for 
C23H43ClNO3
-
 was m/z = 416.29, no such signal was detected for this adduct).  This 
comparative mass spectrometry data was the first indication to us that the 1,3-diol 





Figure 3.12.  ESI-MS (negative mode) of C2-ceramide 2·Cl
-
 adduct.  A solution of 
C2-ceramide 2 (2 mM) and TBACl (6 mM) in CD2Cl2 was injected using MeOH as 
the eluant.  ESI-MS [M+Cl]
-
 calculated for C20H39ClNO3
-
 376.26, found 376.21.  




H NMR Evidence that C2-Ceramide 2 Binds Anions 
 NMR spectroscopy provided more details about the ability of C2-ceramide 2 
to bind Cl
-
 in solution.  Changes in chemical shifts of the –NH and/or –OH protons 
upon addition of anions to a solution of C2-ceramide 2 confirmed that the ceramide 
head-group is a potent anion binder.  In dry CD2Cl2, the two –OH resonances for C2-
ceramide 2 appeared together as a broad signal at  2.68.  Importantly, the 
1
H NMR 
signals for the 1-OH and 3-OH were separated in water-saturated CD2Cl2, allowing us 
to follow changes in chemical shifts during anion titrations (Figure 3.13).  This 
information is in agreement with previous studies of C2-ceramide 2 showing that the 




groups by 1H NMR spectroscopy was only achieved using a combination of low 
concentrations and temperatures in CDCl3).
153 
 
Figure 3.13.  1H NMR of C2-ceramide 2 in dry and wet CD2Cl2 showing resolution 
of the hydroxyl protons in the water saturated CD2Cl2 solution. 
 
 Addition of TBACl to a solution of C2-ceramide 2 in wet CD2Cl2 resulted in 
large downfield shifts for the –NH (= 1.9 ppm) and –OH signals (= 2.3 ppm 
and 2.6 ppm for 1-OH and 3-OH), consistent with formation of hydrogen bonds 
between Cl- and these 3 acidic hydrogen atoms (Figure 3.14).  By evaluating 
chemical shift changes for the –NH proton we determined a Cl- binding constant of 
Ka = 1734  82 M-1 for C2-ceramide 2 in wet CD2Cl2 using WinEQNMR2.154  Similar 
binding constants were determined for the 1-OH (Ka = 1935  65 M-1) and 3-OH (Ka 
= 1877  54 M-1) protons in CD2Cl2.  A Job plot analysis from 1H NMR spectra taken 





Figure 3.14.  Stack plot from 
1
H NMR titrations of C2-ceramide 2 (2 mM) with 
increasing concentrations of tetrabutylammonium chloride (TBACl) in CD2Cl2. 
 
 




 To demonstrate the importance of the ceramide’s 1,3-diol –OH groups in 
anion recognition, we conducted NMR binding experiments with isopropylidene C2-
ceramide 18 (Figure 3.16).  Isopropylidene C2-ceramide 18 had a much weaker 
affinity for Cl
-
 (Ka = 27  0.6 M
-1
) than did C2-ceramide 2.  These results are 
consistant with Hamilton’s synthetic receptor that utilizes four amide –NH and two –
OH functionalities to bind carboxylate anions.
136
  In his system, removal of the two –
OH groups leads to an 800 fold decrease in Ka.  Together the MS and NMR data 
showed that the ceramide head group binds chloride in non-polar CD2Cl2.   
 
Figure 3.16.  Stack plot from 
1
H NMR titrations of isopropylidene C2-ceramide 18 (2 







3.5 Transmembrane Anion Transport by C2-Ceramide 2 




 we envisioned that the amphiphilic C2-ceramide 2 might function well as a 
transmembrane anion carrier.
157
 Ceramides form nm-sized pores in liposomes when 
added at high concentrations (>10 mol%).
158
  We wanted to determine if C2-ceramide 
2 could transport anions across lipid membranes when present at lower 
concentrations, concentrations where transmembrane pores are not formed.  Thus, we 
carried out carboxyfluorescein (CF) release assays to ensure that large channels were 
not formed by C2-ceramide 2 at concentrations of 1 mol%.
159,160
  EYPC liposomes 
were prepared containing 1.5 mM CF and 6 mM p-xylene bis-pyridinium bromide 
(DPX).  In the presence of DPX, CF fluorescence is quenched.  If ceramide pores 
were formed that were large enought to allow release of either the intravesicular CF 
or DPX, then an increase in fluorescence should be observed.  When 1 mol% 
concentrations of either C2-ceramide 2 or isopropylidene C2-ceramide 18 were added 
to these CF liposomes we observed no increase in fluorescence (Figure 3.17), 
indicating that large transmembrane pores were not formed at this particular ceramide 
concentration.  Importantly, we found that higher concentrations of C2-ceramide 2 






Figure 3.17.  C2-ceramide 2 and isopropylidene C2-ceramide 18 were added at a 1 
mol% compound to lipid ratio to a buffered solution of liposomes containing CF and 
DPX.  At these concentrations, no large pores are formed by either compound. 
 
 
Figure 3.18.  C2-ceramide 2 was added at a 15 mol% compound to lipid ratio to a 
buffered solution of liposomes containing CF and DPX.  At this concentration, C2-
ceramide forms pores in the phospholipid membrane large enough for to allow the 
escape of CF and/or DPX.  
 
 To evaluate the ability of C2-ceramide 2 to move Cl
-
 anions across 
membranes we used EYPC liposomes containing 100 mM NaCl and 2 mM lucigenin, 
a chloride-sensitive dye,
161




anions.  Since Cl
-
 quenches lucigenin fluorescence, the facilitated efflux of Cl
-
 from 
liposomes, with concomitant influx of NO3
-
, can be monitored by an increase in 
fluorescence.  Compounds 2 and 18 were added to liposomal solutions at 1 mol%, so 
as to stay below pore-forming concentrations.  Only C2-ceramide 2, and not 
isopropylidene C2-ceramide 18, promoted release of chloride from the liposomes in 
the presence of external nitrate (Figure 3.19).  The contrast in Cl
-
 transport for C2-
ceramide 2 and its blocked derivative 18 demonstrates that ceramide’s 1,3-diol is 
necessary for transporting Cl
-
 across the bilayer.  This is, to our knowledge, the first 
demonstration that low concentrations of ceramides are capable of promoting 
exchange of anions across lipid membranes. 
 
Figure 3.19.  Chloride transport assay using EYPC liposomes (100 nm, 200 M) 
with external nitrate (100 mM NaNO3) in 20 mM HEPES buffer (pH = 7.4).  Upon 
addition of C2-ceramide 2 (2 M, 1 mol%), the increase in lucigenin fluorescence 
indicates Cl
-






 To gain some initial insight into the mechanism by which C2-ceramide 2 
transports anions across lipid membranes, we measured Cl
-




different extravesicular anions.  Thus, EYPC liposomes (100 mM NaCl, 2 mM 
lucigenin, 20 mM HEPES pH 7.4) were added to extravesicular buffers containing 
sulfate anions.  Importantly, when sulfate was the extravesicular anion, little Cl
-
 
efflux above the DMSO baseline was observed following addition of C2-ceramide 2 
(or isopropylidene C2-ceramide 18) (Figure 3.20).  These results are consistent with 
ceramide-facilitated exchange of chloride for the singly charged nitrate anion.  
Sulfate, with its -2 charge and a much higher dehydration energy (G = -1080 
kJ/mol) than Cl
- 
(G = -340 kJ/mol) or NO3
- 
(G = -300 kJ/mol),
162
 is obviously 
more difficult to transport across a bilayer than either of the singly-charged anions.  
That minimal Cl
-
 transport was observed for solutions containing extravesicular SO4
2-
 
supports an anion-exchange mechanism mediated by C2-ceramide 2.  The lack of 
change in lucigenin fluorescence in the presence of extravesicular sulfate also 
provides further evidence that C2-ceramide 2 does not form large pores under these 
condition, as lucigenin would have been released from the vesicle if nM-sized pores 






Figure 3.20.  Chloride transport assay using EYPC liposomes (100 nm, 200 M) 
with external sulfate (75 mM Na2SO4) in 20 mM HEPES buffer (pH = 7.4).  Very 
little activity is observed for either compound.  
 
3.6 Anion Binding and Transport Studies of a C2-Ceramide Derivative with 
Modifications to the Amide Side-Chain 
 
 Following the discovery that C2-ceramide 2 facilitates the transport of 
monovalent anions, we decided to make modifications to the amide chain portion in 
an attempt to test structure-function relationships.  We replaced the –CH3 group of the 
amide side-chain with a trifluoroacetyl group.  The rationale behind this change was 
that the addition of an electron withdrawing group to the corresponding 
trifluoroacetyl C2-ceramide 19 analog should increase the acidity, and therefore the 
hydrogen bond donor ability of the amide –NH.  In fact, equilibrium studies by 
Bordwell on acidities of simple methyl and trifluoro amides in DMSO give pKa’s of 
25.5 and 17.2, respectively for the –NH proton.
163
  Using this trifluoroacetyl C2-
ceramide 19 analog, we hope to find out whether there is a correlation between the 




for an increase in the binding and transport properties of this trifluoroacetyl C2-
ceramide 19 derivative. 
 
3.6.1 Preparation of a Trifluoroacetyl C2-Ceramide Analog 
 The preparation of trifluoroacetyl C2-ceramide 19 involved one step using D-
erythro-sphingosine 3 as the starting material (Scheme 3.2).  Trifluoroacetic 
anhydride was added to a dry CH2Cl2 solution containing sphingosine 3 and 
triethylamine (TEA).  The mixture was allowed to stir overnight at room temperature 
to give trifluoroacetyl C2-ceramide 19 in 65 % yield following purification via 
column chromatography.  Spectroscopic characterization data is in good agreement 
with the two previous literature preparations of trifluoroacetyl C2-ceramide 19.
164,165
  
In these two cases, trifluoroacetyl C2-ceramide 19 was used as a synthetic 
intermediate in the total synthesis of sphingosine 3, where the trifluoroacetyl 
protecting group was removed under basic conditions.  This study is the first, to our 
knowledge where trifluoroacetyl C2-ceramide 19 has been studied as a C2-ceramide 
2 analog. 
 






H NMR Evidence that Trifluoroacetyl C2-Ceramide 19 Binds Anions 
 Addition of TBACl to a solution of trifluoroacetyl C2-ceramide 19 in CD2Cl2 
resulted in smaller downfield shifts (NH = 1.0 ppm) in comparison to that 
observed for C2-ceramide 2 (NH = 1.9 ppm).  However, the two OH signals of 
trifluoroacetyl C2-ceramide 19 have larger downfield shifts by approximately =0.5 
ppm when compared to C2-ceramide 2 (Figure 3.21). By evaluating chemical shift 
changes for the NH proton of trifluoroacetyl C2-ceramide 19, we determined a Cl
-
 
binding constant of Ka = 3361  120 M
-1
 , roughly twice that found for C2-ceramide 2 
(See Table 3.1 for a full list of binding constants).   Addition of the –CF3 does seem 
to enhance the hydrogen bonding ability of C2-ceramide 2. 
 
Figure 3.21.  Stack plot from 
1
H NMR titrations of trifluoroacetyl C2-ceramide 19 (2 






Table 3.1.  Binding constants (Ka) of C2-ceramide 2 and trifluoroacetyl C2-ceramide 
19 with TBACl in CD2Cl2. 
 
Compound Ka ( M
-1
) 2-NH Ka ( M
-1







1734  82 
 
3361  120 
1935  65 
 
3817  386 
1877  54 
 
3628  278 
 
3.6.3 Anion Transport Activity of Trifluoroacetyl C2-Ceramide 19 
 To evaluate the ability of trifluoroacetyl C2-ceramide 19 to transport anions 
across phospholipid membranes, we again used EYPC liposomes containing 100 mM 
NaCl and 2 mM lucigenin in the presence of various external anions.  C2-ceramide 2 
and trifluoroacetyl C2-ceramide 19 both facilitated the release of intravesicular 
chloride from the liposomes in the presence of nitrate.  However, C2-ceramide 2 
showed more activity in this chloride release assay when nitrate was the external 
anion (Figure 3.22).  This result is somewhat surprising due to the fact that the 
binding constants of the trifluoroacetyl C2-ceramide 19 derivative with chloride were 






Figure 3.22.  Chloride transport assay using EYPC liposomes (100 nm, 50 M) with 
external nitrate (100 mM NaNO3) in 20 mM HEPES buffer (pH = 7.4).  The 
compounds were added at a concentration of 2 M (4 mol%).  An increase in 
lucigenin fluorescence indicates Cl
-
 efflux.   
 
 In the next set of experiments, we used the same lucigenin containing EYPC 
liposomes, using bicarbonate as the external anion (Figure 3.23).  Interestingly, the 
trifluoroacetyl C2-ceramide 19 derivative was more active than C2-ceramide 2 when 
bicarbonate was the external anion.  Importantly, when sulfate was used as the 
external anion, little Cl
-
 efflux above background was observed (Figure 3.24).  These 
results correspond to the trifluoroacetyl C2-ceramide 19 derivative facilitating anion 





Figure 3.23.  Chloride transport assay using EYPC liposomes (100 nm, 50 M) with 
external bicarbonate (100 mM NaHCO3) in 20 mM HEPES buffer (pH = 7.4).  The 
compounds were added at a concentration of 2 M (4 mol%).  An increase in 
lucigenin fluorescence indicates Cl
-
 efflux.   
 
 
Figure 3.24.  Chloride transport assay using EYPC liposomes (100 nm, 50 M) with 
external sulfate (75 mM Na2SO4) in 20 mM HEPES buffer (pH = 7.4).  The 
compounds were added at a concentration of 2 M (4 mol%).  Little activity was 





 To ensure we were working below concentrations where ceramide forms large 
pores, we tested these three compounds in CF dye release assays.  EYPC liposomes 
were prepared containing 20 mM CF, a concentration in which CF self-quenches.
160
  
If pores are formed that are large enough to allow the release of CF, an increase in 
fluorescence is observed.  When 4 mol% concentrations of C2-ceramide 2 or 
trifluoroacetyl C2-ceramide 19 were added to these CF liposomes, we observe no 
increase in fluorescence (Figure 3.25a).  This indicates that large transmembrane 
pores were not formed at the concentrations used in the lucigenin assays.  Upon the 
addition of these compounds at 50 mol%, an increase in fluorescence is observed 
corresponding to the formation of pores in the phospholipid bilayer (Figure 3.25b).  
At these concentrations, trifluoroacetyl C2-ceramide 19 is more active at forming 
large pores than is C2-ceramide 2. 
 
 
Figure 3.25.  CF dye release assays.  C2-ceramide 2 and trifluoroacetyl C2-ceramide 
19 were added EYPC liposomes containing 20 mM CF in a 10 mM HEPES buffer at 








 One significant finding in this chapter is the observation that ceramide can 
permeabilize membranes in different ways.  For instance, Colombini and colleagues 
have shown that high concentrations of ceramide lead to the formation of large 
transmembrane pores capable of allowing proteins to cross membranes.
158,166
  In this 
chapter, we have shown that C2-ceramide 2 functions as a transmembrane anion 
transporter at concentrations below those where it self-associates to form the large 
transmembrane pores.  Additionally, we have shown that the trifluoroacetyl C2-
ceramide 19 analog functions as a transmembrane anion transporter that can facilitate 




 better than that of C2-ceramide 2.  Ceramide’s head 
group, with its 1,3-diol and its neighboring amide –NH, is well suited for binding 




.  It may be that ceramide’s ability 
to transport these physiologically relevant anions across lipid membranes is also 













Chapter 4 :  Natural and Synthetic Small Molecules that 
Bind and Transport Bicarbonate  
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4.1 Introduction 
 The goal of the research in this chapter was to study the interactions of 
sphingolipids and small synthetic molecules with bicarbonate anion (HCO3
-
).  This 
chapter will be divided into two parts.  In the first half of this chapter, I will discuss 
work that shows that C2-ceramide 2 and synthetic urea and thiourea-based small 
molecules (28-37) facilitate the transmembrane transport of HCO3
-
 (see Chart 4.1 for 
structures).  Preceding this I will give a brief introduction on the biochemistry of 
bicarbonate anions
-
, highlighting the importance of HCO3
-




will also describe other small molecules known to specifically facilitate the 
transmembrane transport of HCO3
-
.   
 We have also discovered that D-erythro-sphingosine 3 forms a carbamate (27) 
in the presence of HCO3
-
 and CO2.  The second half of this chapter will begin with a 
brief discussion on the chemistry and biochemistry of CO2.  Since we elucidated that 
sphingosine 3 forms carbamates in the presence of HCO3
-
 and CO2, recent research 







4.1.1 Chemistry and Biochemistry of Bicarbonate Anion and Carbon Dioxide 
 Bicarbonate is an organic anion that is relatively small (thermochemical radius 
r, = 1.56 Å) and more basic (pKa [conjugate acid] = 6.4) when compared to other 
biologically relevant anions such as NO3
-
 (r = 1.96 Å, pKa [conjugate acid] = -1.3) 
and Cl
-
 (r = 1.72 Å, pKa [conjugate acid] = -8.0).
106,170
  As depicted in Scheme 4.1, an 
important chemical and biochemical property of the bicarbonate anion is that it is 
both the conjugate acid of carbonate (CO3
2-
) and the conjugate base of carbonic acid 
(H2CO3).  These equilibrium processes make bicarbonate particularly difficult to 
study in terms of binding and transport, in that proper experiments must be designed 
in order to insure that binding, and not acid-base reactions are being observed.   
 Additionally, the amphoteric nature of HCO3
-
 makes it an important buffering 
agent in biological systems.  At physiological pH (~7.2-7.4), both HCO3
-
 and CO2 are 




  This 
equilibrium is important in the CO2 / HCO3
-
 buffer system that helps maintain cellular 
pH, as well as for larger systems in the body.
172
   
 Due to the negative charge associated with bicarbonate anions, they are unable 
to readily pass through a phospholipid bilayer without the assistance of a 
transporter.
171
  In living cells, membrane-bound transport proteins are required to 
facilitate the movement of HCO3
-




Scheme 4.1.  Equilibrium reaction starting with CO2, moving through HCO3
-
 and 
ending with carbonate.   The pKa values are located below the equilibrium arrows.  
Carbonic anhydrases (CA) enhance the rate of the CO2 hydration and HCO3
-
 





4.1.2 Why Study Bicarbonate Transport? 
 Bicarbonate is implicated in a number of important biological processes 
including regulation of physiological pH and respiration.
173
  Table 4.1 lists a few 
additional biological implications of HCO3
-
.  For example, the inability to properly 




 can lead to conditions such as 
cystic fibrosis and heart disease.
106,107,174
   
 
Table 4.1.  Bicarbonate plays a key role in multiple biological functions 
Major Role Target Function Ref. 





Cell Respiration / Metabolism 
Biosynthesis / Metabolism 


















Cellular Signal cAMP Synthase Sperm Activation 
182,183
 



















DNA Cis-Platin Complex 
Carbonic Anhydrase 
Bone Markers 
Anion Exchange Proteins 
Cystic Fibrosis 
Cancer Chemotherapy 
Memory / Alzheimer’s Disease 
Osteoporosis / Bone Resorption 


















4.1.3 Chloride / Bicarbonate Exchange Proteins  
 Carbon dioxide is produced during cellular respiration as a metabolic waste 
product.  Acetyl-CoA is oxidized to CO2 in the Krebs cycle, which is the primary 
source of energy production in the mitochondria.  However, CO2 is poorly soluble in 
aqueous media such as the blood.
106
  Carbon dioxide released during respiration 
diffuses through blood plasma into red blood cells.  Carbonic anhydrases (CAs) then 
catalyze the reversible conversion of CO2 to HCO3
-
, providing a more soluble species 
of CO2 in the blood plasma.
191,192
  The HCO3
-
 is carried to the lungs where it is 
transported back into red blood cells.  In the lungs, CAs then convert bicarbonate 
back to CO2, which is then exhaled through the lungs.  The transport of HCO3
-
 in and 
out of red blood cells is facilitated by specific bicarbonate transport proteins. 
 Anion exchange (AE) proteins, a class of chloride / bicarbonate exchangers, 
facilitate the transport of bicarbonate into and out of red blood cells during 
respiration.  First isolated and studied in 1985, the AE family of chloride / 
bicarbonate exchangers all function through an electroneutral ion exchange 
mechanism.
193,194




 in a 
process that is driven by gradient differences across cell membranes.
195
  Due to their 
important role in respiration, AE proteins represent the most studied class of 
bicarbonate transporters. 
 A second group of bicarbonate transport proteins belong to the SLC26 class of 
proteins.  Misregulation of anions in the kidneys due to faulty SLC26 proteins can 
lead to the formation of kidney stones.
196,197
  Originally determined to function as 






  The SLC26 class of proteins also use an electroneutral 
ion exchange mechanism, exchanging one Cl
-






4.1.5 Small Molecules that Facilitate the Transmembrane Transport of HCO3
-
 
 Bicarbonate anions are incredibly important to biological systems. However, 
there has been surprisingly little research on small molecules that facilitate the 
transmembrane transport of HCO3
-
, and little before 2009.
203
  Currently, there are 
only five papers that specifically discuss this topic; and I am a co-author on three of 
these papers.   
 In Chapter 3, I described research showing that C2 ceramide 2 belongs to a 
small group of natural products that have been shown to facilitate transmembrane 
anion transport.
167
  In this chapter I will present evidence that C2-ceramide 2 also 
belongs to a small group of compounds that are known to specifically transport 
HCO3
-
 across phospholipid membranes.  Prodigiosin 21 is another natural product 









 across phospholipid membranes.
204,205
  In 2009, 
Oluyomi Okunola and Jeffery Davis, in collaboration with Philip Gale and Roberto 
Quesada, published research determining that prodigiosin 21 can also transport 
bicarbonate anions across lipid bilayers.
206
  This was the first paper describing a small 
molecule natural product that can facilitate the transmembrane transport of HCO3
-





Figure 4.1.  Structure of prodigiosin 21, a proposed structure of a prodigiosin 
21·HCO3
-
 complex, and the structure of isopthalimide 38.  
 
 Using NMR spectroscopy, the authors showed that prodigiosin 21 and the 
synthetic isopthalamide 38 bind HCO3
-
 in non-polar solvents, such as CD2Cl2.  In one 
set of experiments, chloride containing liposomes were suspended in a buffer 
containing sulfate.  A Cl
-
 selective electrode was used to monitor the efflux of Cl
-
 
from the liposomes.  Prodigiosin 21 or isopthalamide 38 were added to the liposomal 
solution, and allowed a two minute incubation time to incorporate into the liposomes.  
During this time, no appreciable amount of Cl
-
 was observed to be released from the 
liposomes.  Upon the addition of HCO3
-
 to the liposomal solution, an increase in 
extravesicular chloride was observed, suggesting that prodigiosin 21 and 




 across phospholipid 
membranes. 
 However, these experiments only provided indirect evidence of bicarbonate 
transport.  In order to monitor the transport of bicarbonate directly, the authors 
introduced a new 
13














peaks gave distinct signals in the 
13











 into the baseline.  These experiments show that both prodigiosin 21 





phospholipid membranes (Figure 4.2). 
 
Figure 4.2.  
13





 exchange.  The titration sequence for monitoring the transmembrane 
transport of bicarbonate ions is as follows:  
13
C NMR spectra (i) before and (ii) after 




; (iii) after the 
addition of prodigiosin 21, isopthalamide 38 or DMSO blank; (iv) after the addition 
of Mn
2+
.  Figure used with permission from reference 206. 
 
 Another small molecule that was recently determined to transport bicarbonate 
across lipid bilayers is octafluorocalix[4]pyrrole 39 (Figure 4.3).
207
  In contrast to the 
non-fluorinated calixpyrrole, which had limited anion transport properties, Sessler, 
Gale, and Quesada discovered that the fluorinated derivative had a much higher 




substituents that increase the acidity, and therefore, the hydrogen bond donor ability 
of the pyrrole units.  The authors found that octafluorocalix[4]pyrrole 39 allows for 




 using the same ion sensitive electrode liposome 
experiments as described above. 
 





 In two recent collaborative papers, the Davis and Gale groups identified two 





phospholipid membranes (Figure 4.4).
168,169
  Both urea and thiourea derivatives were 
able to bind anions, but only the thiourea analogs were able to transport anions in ion 
sensitive electrode and 
13
C NMR assays.  My contributions to these papers will be 










4.2 C2-Ceramide 2 Binds and Transports HCO3
-
 
 To determine that C2-ceramide 2 binds bicarbonate anions, 2 mM solutions of 
C2-ceramide 2 in CD2Cl2 were prepared with increasing amounts of 
tetraethylammonium bicarbonate (TEAHCO3).  Large downfield shifts of the –NH 
proton (= 1.8 ppm) were observed (Figure 4.5).  Unfortunately, we could not 
follow the shift of the –OH protons as addition of TEAHCO3 to solutions of C2-
ceramide 2 led to the disappearance of the –OH signals.   Additionally, these spectra 
were further complicated by the appearance of small signals at   4.4, 4.8, and 6.9 
ppm.  While it is unclear exactly what gives rise to these signals, we believe they may 
correspond to the binding of C2-ceramide 2 to a small amount of carbonate in 
solution.  By evaluating the chemical shift changes for the –NH proton, we 
determined a HCO3
-
 binding constant of Ka = 1933  58 M
-1
 for C2-ceramide 2 in 
CD2Cl2, using the WinEQNMR2 program.
154
  The binding constant for HCO3
-
 is 
consistent with that found for C2-ceramide 2 and Cl
-







Figure 4.5.  Stack plot from 
1
H NMR titrations of 2 mM solutions of C2-ceramide 2 
with TEAHCO3 in CD2Cl2.  The line shows the change in the chemical shift of the 
C2-ceramide 2 amide –NH signal with increasing concentration of TEAHCO3. 
 
 To evaluate the ability of C2-ceramide 2 to facilitate the transport of 
bicarbonate anions across phospholipid bilayers, EYPC liposomes were prepared 
containing 100 mM NaCl and 2 mM lucigenin, a chloride-sensitive dye.
208
  The 
liposomes were suspended in an extravesicular buffer containing bicarbonate anions.  
Since Cl
-










Figure 4.6.  Chloride transport assay using EYPC liposomes (100 nm, 200 m) 
containing Cl
-
 and lucigenin, with external bicarbonate (100 mM) in a 20 mM HEPES 
buffer (pH = 7.4).  C2-ceramide 2 and isopropylidene C2-ceramide 18 were added at 
concentrations of 1 mol % (relative to phospholipid concentration). 
 
 Following the addition of C2-ceramide 2 (2 M, 1 mol %) to liposomes 
suspended in a bicarbonate buffer, an increase in the fluorescence of lucigenin was 
observed (Figure 4.6).  If the external bicarbonate was replaced with sulfate anions, 
little fluorescence increase was observed (Figure 4.7).  This result is consistent with 
ceramide-facilitated exchange of chloride and bicarbonate.  Addition of the protected 




 exchange across the 
liposomal membrane.  For comparison purposes, Figure 4.7 shows fluorescence data 
from the chloride transport assays with various external anions using C2-ceramide 2.  
C2-ceramide 2 facilitated the exchange of intravesicular chloride when either 
bicarbonate or nitrate was the external anion.  When sulfate was the external anion, 






Figure 4.7.  For comparison purposes, fluorescence data from the chloride transport 
assays using C2-ceramide 2 is plotted as a function of initial fluorescence (F0).    
 
 These results put C2-ceramide 2 into a small group of naturally-occurring 
small molecules that facilitate transmembrane bicarbonate transport, with prodigiosin 
21 being the only other natural product shown to transport bicarbonate.  Additionally, 




 in natural 
systems.  For instance, cystic fibrosis (CF) is caused by mutations in the CF 





 transport across lung epithelial cell membranes.
107
  
Recently, Worgall and colleagues found that cells with defective CFTR show an 
increase in production of sphingolipids, including various ceramides.
209
  Our results 
suggest that this increase in ceramide accumulation may be the cells’ attempt to 






4.3 Tren-Based Small Molecules: A New Class of Bicarbonate Transporters 
  Bicarbonate is a biologically important anion.  In a collaboration between the 
Davis and Gale labs, we set out to determine if tris(2-aminoethyl)amine (tren) based 
compounds could facilitate the transport of HCO3
-
 across phospholipid membranes.
168
  
Previous studies have shown that tren-based compounds can have various membrane 





 symport across CH2Cl2 “membranes” in U-tube 
experiments.
210
  In Smith’s experiments, two aqueous layers were separated by an 
organic layer.  The water layer on one side was doped with HCl.  Transport of HCl by 
tren 40 was monitored by a change in pH in the water layer on the other side.   
 
Figure 4.8.  Examples of membrane active tren-based amides. 
 In another example, Brad Smith has demonstrated that tren-based amides can 
act as synthetic phospholipid flippases.
211
  Smith was able to show that tren 41 was 
able to facilitate the translocation of anionic phospholipid mimics across surface 
differentiated vesicles.  He proposed that tren 41 binds with the negatively charged 




carries the head group along with it, causing the phospholipid to move from the outer 
leaflet of the phospholipid bilayer to the inner leaflet. 
 Additionally, Sofia Berezin in the Davis lab has shown that a bis-catechol tren 
based receptor 25 is capable of transmembrane chloride transport.
150
  For a more 
detailed description of this work, see Section 3.3.2. 
 
4.4  Thiourea Tren-Based Receptor Facilitates the Transport of HCO3
-
 
 In collaboration with the Gale group, we have discovered a new class of 
bicarbonate transporters.
168
  Synthesized by members of the Gale group, these 
compounds are based on a tren scaffold, containing either tris-urea or tris-thiourea 
functionalities (Figure 4.9a).  NMR titrations in d6-DMSO/0.5% H2O with 
tetrabutylammonium chloride gave binding constants of 658, 830, 447, and 191 M
-1
 
for compounds 28-31, respectively.  Additionally, single crystals of a carbonate 
complex of tren 31 were grown by slow evaporation of DMSO/water solution in the 
presence of excess tetraethylammonium bicarbonate.  The solid state structure 
revealed that two equivalents of tren 31 bind to a single carbonate anion via 12 






Figure 4.9.  a) Tren-based anion receptors 28-31 synthesized by the Gale group. b) 
Crystal structure of two tren 31 molecules with a single bound carbonate anion.  
 
 The Gale group studied the transport capabilities of these tren analogs via ion 
sensitive electrode experiments.  Chloride containing liposomes were suspended in a 
buffer containing sulfate.  A chloride-sensitive electrode was used to monitor the 
efflux of Cl
-
 from the liposome.  In separate runs, each of the tren-based receptors 
were added to the liposomal suspensions and allowed to incubate for two minutes.  
Upon the addition of HCO3
-
 to the liposomal solution, an increase in extravesicular 




 exchange.  Tren 
28, which contains butylurea groups, did not transport chloride under these conditions 
(Figure 4.10). Tren 29, which has three phenyl urea groups, allowed for a small 
amount of chloride to be released from the liposome.  However, the thiourea 
appended tren receptors 30 and 31 were the most active in this assay, suggesting that 









Figure 4.10.  Chloride sensitive electrode studies with tren receptors 28-31.   
 However, these experiments only provided indirect evidence of bicarbonate 
transport, as this experiment monitors the movement of HCO3
-
 as a consequence of 
Cl
-
 efflux.  The most commonly used methods for monitoring anion transport are 
those that use chloride-sensitive electrode
168,207
 or fluorescence based assays using the 
chloride sensitive dye lucigenin (previously described in Section 3.5).
54,167,208,212,213
  
In both cases, the anion that is monitored is chloride, giving only indirect evidence of 
the transmembrane movement of HCO3
-
.   
 In order to observe the transport of bicarbonate directly, I tested the tren 
compounds 28-31 in a 
13









, with sulfate 





distinct signals in the 
13
C NMR spectrum (Figures 4.11 and 4.12).  In the final step of 
this experiment, MnCl2 is added to the NMR tube.  When MnCl2 binds with the 




this line broadening agent cannot cross the phospholipid membrane, therefore leaving 
the signal for encapsulated bicarbonate unaffected. 
 
 
Figure 4.11.  
13






 To directly evaluate the ability of tren 28-31 to transport bicarbonate, EYPC 




 were prepared in HEPES buffer at pH = 7.4.  







Figure 4.12 shows the 
13
C NMR of this liposome solution a) before and b) after 
addition of a NaCl pulse that brings the final concentration of Cl
-
 to 50 mM.  Tren 28-
29 (4 mol%) or a DMSO blank were added to the liposome solution (Figure 4.12c) 
and another 
13
C NMR spectra was obtained.  The final spectra were taken following 
the addition of MnCl2 (0.5 mM final concentration), a paramagnetic line broadening 





Figure 4.12.  
13






 exchange promoted by 4 mol% of 
receptors 28-31  a) before and b) after addition of a 50 mM NaCl pulse to EYPC 
vesicles containing 100 mM NaH
13
CO3 buffered to pH 7.4 with 20 mM HEPES, 
dispersed in 75 mM Na2SO4 buffered to pH 7.4 with 20 mM HEPES; c) following 
addition of 28-31 or DMSO; d) following addition of 0.5 mM MnCl2, a paramagnetic 




C NMR experiments provide direct evidence that the tren thioureas 30 
and 31 readily transport bicarbonate across phospholipid membranes in the presence 
of external chloride.  Additionally, in results consistent with chloride sensitive 
electrode experiments, in that tren urea 28 showed no transport activity, while tren 
urea 29 showed only modest activity.  No changes were noted in the 
13
C NMR 






 anion exchange mechanism facilitated by tren thioureas 30 and 31.   
 
4.5  Structurally Simple Thiourea-Based Bicarbonate Transporters 
 With the knowledge that thiourea-based tren receptors transport bicarbonate 






  In another collaborative effort with the Gale group, 
simple urea and thiourea receptors 32-37 were prepared (Figure 4.13). 
 
Figure 4.13.  a) Structurally simple urea- and thiourea-based receptors. b) Model 
illustrating possible complex between thiourea 37 and bicarbonate. 
 
 The Gale group studied the transport capabilities of these simple urea and 
thiourea analogs via ion sensitive electrode experiments.  Chloride containing 
liposomes were suspended in a buffer containing sulfate.  A chloride sensitive 
electrode was used to monitor the efflux of Cl
-
 from the liposome.  In separate runs, 
each of the receptors were added to the liposomal suspensions and allowed to 
incubate for two minutes.  Upon the addition of HCO3
-
 to the liposomal solution, an 




 exchange.  Results from these experiments showed that only the thiourea 
compounds 33, 35, and 37 are capable of bicarbonate transport, while the urea 
receptors exhibited little activity above the DMSO baseline (Figure 4.14).  Again, the 






Figure 4.14.  Chloride sensitive electrode studies using compounds 32-37. 
 To directly evaluate the ability of urea and thiourea receptors 32-37 to 




 were prepared 







.  Figure 4.15 shows the 
13
C NMR of this liposome 
solution a) before and b) after addition of a NaCl pulse that brings the final 
concentration of Cl
-
 to 50 mM.  Compounds 32-37 (4 mol%) or a DMSO blank were 
added to the liposome solution (Figure 4.15c) and another 
13
C NMR spectra was 
obtained.  The final spectra were taken following the addition of MnCl2 (0.5 mM final 
concentration), a paramagnetic line broadening agent that only affects external 














 exchange promoted by 4 mol% of 
receptors 32-37  a) before and b) after addition of a 50 mM NaCl pulse to EYPC 
vesicles containing 100 mM NaH
13
CO3 buffered to pH 7.4 with 20 mM HEPES, 
dispersed in 75 mM Na2SO4 buffered to pH 7.4 with 20 mM HEPES; c) following 
addition of 32-37 or DMSO; d) following addition of 0.5 mM MnCl2, a paramagnetic 







C NMR experiments provide direct evidence that the thiourea 
receptors 33, 35, and 37 readily transport bicarbonate across phospholipid membranes 







exchange mechanism facilitated by the thiourea analogs.  Additionally, in results 
consistent with chloride sensitive electrode experiments, the urea receptors 32, 34, 
and 36 showed little activity in the 
13
C NMR assay. 
 In conclusion, in collaboration with the Gale group we have discovered new 
thiourea-based small molecules that facilitate the transmembrane transport of the 
biologically important bicarbonate anion.  Through both indirect and direct liposome 







anion exchange mechanism, while the urea receptors show little to no activity.  Our 
results clearly show that the thiourea analogs are significantly better at transporting 
bicarbonate anions than the corresponding ureas.  While Davis and Smith have seen 
similar effects on chloride transport using functionalized cholapods,
214
 the studies 
presented here are the first time such trends have been noted for bicarbonate 
transport.  To our knowledge, these results represent two of only five papers on small 
molecule bicarbonate transporters. 
 
4.6 Biological and Environmental Impacts of Carbon Dioxide 
 Carbon dioxide is a neutral gas that can diffuse across phospholipid 
membranes.
106
  However, its low solubility in aqueous environments can slow this 




Henry’s Law states that at a constant temperature, the concentration (c) of a dissolved 
gas is proportional to the partial pressure (p) of the gas in equilibrium with the liquid.   
 
 Solubility of a gas in a particular solvent can be given as Henry’s law constant 
(kH).  For comparison purposes, Table 4.2 lists kH for CO2 in H2O, DMSO, and 
CH2Cl2.  Lower kH values indicate that the concentration of dissolved gas is higher 
with lower partial pressures of gas above the solvent.  In this case, CO2 is the most 
soluble in CH2Cl2 as the kH value is the smallest, and the least soluble in H2O.   
 
Table 4.2.  Henry’s Constants (kH) for CO2 in Select Solvents 











 In certain instances, evidence suggests that aquaporin (AQP) water channels 
may also facilitate the transport of CO2 across phospholipid membranes.
219
  Research 
from the Gros group shows that human red blood cells lacking AQP-1 have a 60 % 
decrease in transmembrane CO2 transport.
220
  Recently, the Gros group also identified 
the RBC Rhesus complex protein, RhAG as an additional protein in red blood cells 
that also functions as a CO2 channel.
221
  This suggests that AQP-1 and RhAG work 
together with the bicarbonate transport proteins of red blood cells to play important 
roles in cellular respiration through the removal of waste HCO3
-




 Carbon dioxide is one of the major greenhouse gases and is the major product 
of combustion of organic matter.
222
  Some of the main sources of atmospheric CO2 
are energy production through the combustion of fossil fuels, decaying plant matter, 
and a respiratory waste product of animals.  An important method used for 
greenhouse gas reduction from fossil fuel based energy production is a process known 
as post-combustion capture.  Aqueous amine solutions or polymer bound amines are 
used in scrubbers to remove CO2 waste before it enters the atmosphere.
223-227
  These 





Scheme 4.2.  Reversible carbamate formation between two primary amines and one 
molecule of CO2. 
 
4.7 Supramolecular Carbamate-Forming Systems 
 
 Research in the lab of Dmitry Rudkevich took advantage of carbamate 
formation to drive the self-assembly of supramolecular structures.  During the early 
portions of this decade, his work focused on the use of supramolecular containers 
such as hemicarcerands and calixarenes to encapsulate gases such as He, H2, N2, NO, 
N2O, and CO2.
229-232
  Following this work, Rudkevich began to use gases, such as 






 Under physiological conditions, the N-terminus of peptides have been shown 
to form carbamates in the presence of CO2.
234
  Using the amino acid lysine, 
Rudkevich developed a small dipeptide 38 that takes advantage of carbamate 
chemistry to form reversible linear supramolecular polymers.
235
  Bubbling CO2 
through a solution of this lysine peptide in DMSO gave rise to carbamate formation, 
as the amino group of lysine reacts with CO2.  The carbamate anion formed on one of 
the amino groups forms a hydrogen bond with an RNH3
+
 group on a neighboring 
peptide to produce a linear polymer 39.  The labile nature of carbamate chemistry 
allows this reaction to be reversible.  Simply heating the solution forces the 
equilibrium in the opposite direction, as CO2 is released and the lysine peptide returns 
to its monomeric form. 
 
Figure 4.16.  Linear supramolecular polymer that traps CO2 via carbamate formation.   
 
 In order to more closely study carbamate formation of this molecular 
assembly, Rudkevich also prepared a simple mono-lysine analog 40.  Since this 
analog contained one free amine per subunit, only dimers, as opposed to long 
polymers, could be formed.  Upon bubbling CO2 into a 1 M solution of 40 in CDCl3, 




H NMR spectroscopy.  In the 
13
C 
NMR spectrum, a new signal at  161 ppm was observed, corresponding to the 
carbonyl carbon of the newly formed carbamate.  However, the 
1
H NMR spectra gave 




% of the mono-lysine 40 formed a carbamate.  The other half became protonated at 
the primary amine of lysine, and the ammonium carbamate 41 was formed.  The 
1
H 
NMR spectrum of ammonium carbamate 41 showed two 1:1 signals at  2.74 ppm 
and  2.94 ppm, corresponding to the -CH2NH of the ammonium and carbamate 
halves, respectively.  Additionally, the peak corresponding to the methylene protons 
of the ammonium half shifted downfield approximately  0.25 ppm from that of the 
same methylene protons of the neutral mono-lysine 40 precursor.  Interestingly, when 
d6-DMSO was used as the solvent, no signals were observed for the protonated amine 
half.  In this case, CO2 quantitatively reacted with mono-lysine 40 to form the 
corresponding carbamic acid.  
 
Figure 4.17.  Mono-lysine 40 forms an ammonium carbamate salt 41 upon bubbling 
with CO2 in CDCl3. 
 
 The solvent dependence of carbamate formation between amines and carbon 
dioxide has also been thoroughly studied by Yoshikatsu Ito and collegues.
236
   In this 
study, the authors test carbamate formation of 3-(1-naphthyl)propylamine 42 and CO2 
in a variety of solvents.  The results of these studies are similar to the solvent 
dependence observed by Rudkevich.
237,238
  Upon bubbling CO2 into a solution of 42 





NMR evidence suggests quantitative conversion of 42 to the corresponding carbamic 
acid 43.  In the 
1




with the -CH2NH shifted downfield approximately  0.40 ppm from that of the free 
amine.  A signal at approximately  163 ppm was observed in the 
13
C NMR spectrum 
corresponding to the carbonyl of the carbamic acid 43.   
 
Figure 4.18.  Ito’s 3-(1-napthyl)propylamine 42 forms carbamic acid 43 or 
ammonium carbamate 44 in a solvent dependent manner. 
  
 Upon bubbling CO2 through solutions of 42 in CDCl3 or d8-isopropanol, the 
ammonium carbamate 44 was observed.  The 
1
H NMR spectrum of 44 in CDCl3 
showed a doubling of signals corresponding to the -CH2NH protons of the 
carbamate half and the ammonium half.  A signal corresponding to the carbonyl of 
the carbamate was observed at  163 in the 
13
C NMR spectrum. 
 The authors also note that the carbamic acid and the carbamate are 
indistinguishable via NMR spectroscopy.  However, the neutral carbamic acid is 
assumed to be the major product in solvents such as d6-DMSO, as no ammonium 






4.8 Anion Binding and Transport Properties of Sphingosine 3  
 With the knowledge that C2-ceramide 2 binds and transports anions, we 
sought to determine if its precursor, sphingosine 3, would do the same.  Sphingosine 
3 differs from C2-ceramide 2 in that it contains a primary amine instead of the amide 
functionality at the ceramide C2 position.  
 
Figure 4.19.  C2-ceramide 2 and sphingosine 3.  
 In order to determine if sphingosine 3 binds chloride, we used NMR 
spectroscopy.  Thus, 2 mM solutions of sphingosine 3 were prepared in CD2Cl2 with 
increasing amounts of TBACl added to the solution.  Unfortunately, unlike C2-
ceramide 2, the signals corresponding to the hydroxyl protons of sphingosine 3 were 
not observed in CD2Cl2.  Upon adding increasing concentrations of TBACl to the 
solution, some clear changes were observed for the protons in the head group of 
sphingosine 3 (Figure 4.20).  The signals corresponding to the protons alpha to the    
–NH2 and secondary –OH moved downfield approximately δ 0.19 ppm.  
Additionally, the signals for the diastereotopic protons adjacent to the primary –OH 
changed significantly upon addition of TBACl to the solution.  We attribute these 
shifts to conformational changes associated with sphingosine 3 binding Cl
-





Figure 4.20.  Titrations of sphingosine 3 with TBACl in CD2Cl2 give rise to small 
shifts in the head group protons. 
 
 With the knowledge that sphingosine 3 can bind Cl
-
 in CD2Cl2, we wanted to 
determine if sphingosine 3 could facilitate anion transport across phospholipid 
membranes.  To do this, we utilized the 
13
C NMR assay previously described in 




 were prepared in 20 mM 







.  Figure 4.21 shows the 
13
C NMR of this liposome 
solution a) before and b) after addition of a NaCl pulse that brings the final 
concentration of Cl
-
 to 50 mM.  Sphingosine 3 (4 mol%) or a DMSO blank were 
added to the liposome solution (Figure 4.21c) and another 
13




obtained.  The final spectra was taken following the addition of MnCl2 (0.5 mM final 
concentration), a paramagnetic line broadening agent that only affects external 
bicarbonate.   
 
Figure 4.21.  Initial 
13







 exchange.  Sphingosine 3 does not facilitate the exchange bicarbonate 
with chloride under these conditions. 
 







exchange across the liposomal membrane.  The spectra obtained during the 
sphingosine 3 tests look the same as the DMSO blank.  The signal at approximately  




 remains unchanged upon addition 
of sphingosine 3 (or the DMSO blank) to the liposomal solution.  Upon the addition 




 was broadened into the baseline 
leaving a prominent signal for the internal bicarbonate that was not transported out of 




to find a possible explanation for the lack of anion transport by sphingosine 3.  Since 
this assay also relies on the ability of sphingosine 3 to bind and transport bicarbonate, 
we wanted to determine if sphingosine 3 could bind HCO3
-
 in organic solvents. 
 
4.9 Sphingosine 3 forms Carbamates in the Presence of HCO3
-
 in CD2Cl2 
 Having shown that sphingosine 3 binds Cl
-
, but does not facilitate the anion 
exchange of chloride with bicarbonate, we sought to determine if sphingosine 3 
would bind HCO3
-
.  Titration of a 2 mM solution of sphingosine 3 in CD2Cl2 with 
increasing amounts of TEAHCO3 gave rise to a new 
1
H NMR signal that shifts 
initially from approximately δ 4.51 ppm (after addition of 0.75 eq. TEAHCO3) to δ 
5.38 ppm (after addition of excess TEAHCO3).  This new signal corresponds to the    
–NH of the sphingosine carbamate 27 (Figure 4.22).  Additionally, the signals at δ 
2.70 and δ 3.99 ppm of sphingosine 3 disappear with increasing concentrations of 
TEAHCO3, with the concurrent appearance of signals at δ 3.57 and δ 4.11 ppm.  An 
expanded view of the spectra of 2 mM sphingosine 3 with 3 eq. TEAHCO3 can be 
seen in Figure 4.23, labeled with the diagnostic signals from protons of each species.  
At these concentrations, sphingosine 3 and the sphingosine carbamate 27 exist in an 
approximately 1:1 ratio.  In this spectrum, a new signal corresponding to the 
carbamate –NH appears at  4.77 ppm.  The –CH protons in the new sphingosine 
carbamate 27 headgroup are downfield shifted from the protons in sphingosine 3.  
The signal corresponding to the proton alpha to the secondary alcohol shifts 




-CHNH proton shifts from  2.75 to  3.59 ppm.  Additionally, doubling of the 




















Figure 4.22.  Titration of sphingosine 3 with TEAHCO3 in CD2Cl2 shows the 






Figure 4.23.  
1
H NMR spectrum following the addition of 3 eq. of TEAHCO3 to a 2 
mM solution of sphingosine 3 in CD2Cl2.  This gives approximately a 1:1 mixture of 
sphingosine 3 and sphingosine carbamate 27.  
 
 In order to gain 
13
C NMR evidence for carbamate formation by sphingosine 3, 
we needed to use higher concentrations of the sphingolipid.  Increasing the 
concentration of sphingosine 3 to 20 mM in CD2Cl2 allowed for complete conversion 
(by 
1
H NMR) to sphingosine carbamate 27 following the addition of only 1.5 eq. of 
TEAHCO3 (Figure 4.24).  Figure 4.25 shows the 
13
C NMR spectra of the same 
samples.  Upon the addition of 1.5 eq. TEAHCO3 to a solution of sphingosine 3 in 
CD2Cl2, two signals appeared in the C=O region of the 
13
C NMR spectra between  
160 and  170 ppm.  The signal at  166 ppm corresponds to the carbonyl of the 
sphingosine carbamate 27, while the smaller signal at  161 ppm corresponds to the 
excess TEAHCO3.  The carbon alpha to the –NH of sphingosine carbamate 27 shifts 
downfield approximately 2 ppm from  58.1 to 60.2 ppm when compared to 
sphingosine 3.  Additionally, changes in the olefinic region between  130 and  140 





Figure 4.24.   
1
H NMR of a) sphingosine 3, b) sphingosine carbamate 27, and c) 
TEAHCO3 blank in CD2Cl2.  
 
 
Figure 4.25.  
13
C NMR of a) sphingosine 3, b) sphingosine carbamate 27, and c) 




4.10  Sphingosine Carbamate 27 Formation via CO2 Bubbling 
 Following the discovery that sphingosine 3 forms a carbamate in CD2Cl2 in 
the presence of TEAHCO3, we wanted to see if we could form sphingosine carbamate 
27 in the presence of CO2 in a similar manner to that of Dmitry Rudkevich (Section 
4.7).  The apparatus used to bubble CO2 through a solution containing sphingosine 3 
is shown in Figure 4.10.   
 
Figure 4.26.  CO2 bubbling apparatus. 
 
 The CO2 bubbling apparatus is comprised of a two neck round bottom flask 
containing dry ice with a pressure release valve attached to one neck.  A cannula runs 
from the flask into a sample vial containing the sample with an additional needle 
inserted into the vial to allow the CO2 to escape once bubbled through the solvent.  
Typically, a 15 mM sample was prepared in 2 mL of solvent and degassed with N2 
for 20 minutes prior to bubbling CO2 through the solution. 
 A 15 mM sample of sphingosine 3 was prepared in CD2Cl2.  Following a N2 
purge, CO2 was bubbled through the sample for 1 hour.  Unfortunately, no change in 
the 
1
H NMR spectrum was observed.  Additional attempts to form a carbamate from 




primary amine of sphingosine 3 was deprotonated, also failed to show 
1
H NMR 
evidence for carbamate formation. 
 With no carbamate formation in non-polar CD2Cl2, we decided to switch to a 
more polar solvent in DMSO.  In previously discussed studies, Rudkevich and Ito 
were able to quantitatively form carbamic acids using the more polar DMSO as a 
solvent (Section 4.7).  A 15 mM solution of sphingosine 3 was prepared in d6-
DMSO, purged with N2, and then CO2 was bubbled through the solution for 1 hour.  
Figure 4.27 shows the 
1
H NMR spectrum of the d6-DMSO blank, as well as before 
and after bubbling with CO2.  The appearance of a new signal at  6.12 ppm 
corresponds to the –NH proton of the sphingosine carbamate 27.  The ratio of 
sphingosine 3 to sphingosine carbamate 27 was roughly 1:1 following one hour of 
exposure to CO2.  A new signal at  4.15 ppm corresponds to the proton alpha to the 
secondary –OH of sphingosine carbamate 27, and is shifted downfield from the same 
proton of sphingosine 3 by approximately 0.25 ppm.  Additionally, doubling of the –
OH and olefinic protons was observed between  4.30-5.80 ppm. 
 The 
13
C NMR spectra of the same three samples can be found in Figure 4.28.  
The new signal at  157 ppm corresponds to the carbonyl carbon of the sphingosine 
carbamate 27 that is formed upon reaction with CO2.  Doubling of the carbon signals 
corresponding to the head group carbons ( 57.0-73.0 ppm) and the olefinic carbons 





Figure 4.27.  
1
H NMR of a) CO2 blank, b) sphingosine 3, and c) sphingosine 




Figure 4.28.  
13
C NMR of a) CO2 blank, b) sphingosine 3, and c) sphingosine 








C NMR data obtained from bubbling CO2 through solutions 
of sphingosine 3 in d6-DMSO suggested the formation of a sphingosine ammonium 
carbamate 45 (Figure 4.29).  The 1:1 ratio of signals and the chemical shifts of these 
signals is consistent with results from mechanistic studies of carbamate formation 
using CO2 with simple monoethanolamines,
228
 as well as the more complicated 




 (Section 4.7). 
 
Figure 4.29.  Sphingosine ammonium carbamate 45 formed upon bubbling CO2 
through a solution of sphingosine 3 in d6-DMSO.  
 
 However, this differs from previously described work in that Rudkevich and 
Ito were able to get full conversion to carbamic acids in d6-DMSO.  In an attempt to 
push the CO2 induced conversion of sphingosine 3 to sphingosine carbamate 27 in d6-
DMSO to completion, longer bubbling times were studied.  Figure 4.15 shows 
1
H 
NMR spectra of 15 mM solution of sphingosine 3 bubbled with CO2 for 1 and 4 
hours.  Interestingly, no change in the chemical shifts or integration was observed 
when increasing the CO2 bubbling time.  In each case, a 1:1 ratio of protonated 





6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm 
Figure 4.30.  1 vs. 4 hours bubbling CO2 through a 15 mM solution of sphingosine 3 
in d6-DMSO.  
 
 In these studies, we found that sphingosine 3 forms an ammonium carbamate 
salt 45 in DMSO upon bubbling with CO2, which differs from other studies on 
carbamate formation.  In stark contrast to our findings, Rudkevich and Ito determined 
that bubbling CO2 through amine solutions only gave ammonium carbamate salts in 
non-polar organic solvents such as chloroform.  They found that in highly 
competitive, polar aprotic solvents such as DMF and DMSO, the neutral carbamic 
acid is favored over the charged ammonium carbamate salts.  However, we have 
found that the sphingosine 3 forms the corresponding ammonium carbamate 45 that is 
stable in DMSO.  It is possible that the stability of the sphingosine ammonium 
carbamate 45 in DMSO may be attributed to the 1,3-diol units in the sphingosine 3 




sphingosine ammonium carbamate 45, where both intra- and intermolecular hydrogen 
bonding by the –OH groups provide additional stabilization. 
 
Figure 4.31.  Model of a possible conformation of the sphingosine ammonium 




 In this chapter, I described work that led to the discovery of transmembrane 
transporters for bicarbonate using chloride sensitive electrode, fluorescence, and 
13
C 
NMR assays.  In collaboration with the Gale group, we determined that tris thioureas 






 anion exchange mechanism.  
Additionally, we developed simple bicarbonate transporters 33, 35, and 37 that take 
advantage of a thiourea functionality to bind and transport bicarbonate.  Another 
significant finding in this chapter is that the natural product, C2-ceramide 2, binds 
and transports bicarbonate.  C2-ceramide 2, along with prodigiosin 21, are the only 





 An additional finding described in this chapter is the observation that the 
natural product sphingosine 3 forms sphingosine carbamate 27 in the presence of 
bicarbonate in methylene chloride, or in the presence of carbon dioxide in DMSO.  In 
DMSO, sphingosine 3 forms an ammonium carbamate salt 45, which differs from 
other studies on carbamate formation.  In separate studies, Rudkevich and Ito found 
that bubbling CO2 through amine solutions in DMSO yield quantitative conversion to 
the corresponding carbamic acid.  In our case, the sphingosine ammonium carbamate 
45 seems to be quite stable in DMSO.  This may be due to additional stabilization via 
hydrogen bonding from adjacent –OH groups in the sphingosine 3 head group.  These 
results also suggest that sphingosine 3 may exist as a carbamate in natural systems 
where sufficient amounts of HCO3
-
















Chapter 5 : Conclusions and Future Directions 
 
 Ceramides are known to be involved in a number of cellular processes, 
including cell differentiation, autophagy, cell senescence, skin water barrier 
homeostasis, and apoptosis.
1-5
  Due to the fact that ceramides are so important for cell 
metabolism, there is a need to better understand the molecular mechanism that they 
use to impart function. 
 One significant finding in this work is the observation that C2-ceramide 2 can 
permeabilize phospholipid membranes in various ways. Interesting findings by 
Colombini suggest that C16-ceramide 1 and C2-ceramide 2 may induce apoptosis by 
forming large, stable pores in phospholipid membranes.
7
  By appending ester 
functionalities to the –OH groups of C2-ceramide 2, we have discovered a compound 
that may be more active in forming pores than the amphiphilic natural product.  In 
fact, C2-diacetate 16 forms pores in phospholipid membranes that are large enough to 
release the apoptosis-inducing cytochrome c. 
 However, large pore formation is not the only way that C2-ceramide 2 can 
permeabilize membranes.  At concentrations below that which C2-ceramide 2 forms 
transmembrane pores, we have discovered that C2-ceramide 2 facilitates the transport 
of the biologically important chloride and bicarbonate anions through an anion 
exchange mechanism.  It may be that ceramide’s ability to transport these 
physiologically relevant anions across lipid membranes is also important in vivo. 
 With ceramide being important in a variety of biological systems, there is a 
great need to understand how ceramide is able to impart function.  As organic 




ceramide through the development of synthetic analogs.  Synthetic ceramide analogs, 
such as the compounds in Chart 5.1, may better help us understand structure-function 
relationships of how ceramide derives its membrane activity.   
Chart 5.1 
 
 Compounds 47-49 should be easily accessible using commercially available 
starting materials such as glycerol (47 and 48) or serine (49).  Like C2-ceramide 2, 
these compounds each contain three hydrogen-bond donor groups in the hydrophilic 
head-group, and are connected via an amide linkage to a lipophilic tail.  In fact, 
members of the Davis group are currently studying these compounds and already 
have some interesting preliminary results in anion transport assays. 
 Additionally, in Chapter 4 I described synthetic small molecules 30, 31, 33, 
35, and 37 that are able to facilitate the transmembrane anion transport.  In 
collaboration with the Gale group, we found that only the thiourea versions of these 
compounds were membrane-active.  Based on these results, it is reasonable to believe 
























Chapter 6 : Experimental Procedures 
 
6.1 General Experimental 
 All 
1
H NMR spectra were recorded on a Bruker DRX-400 or a Bruker 
Advance 400 instrument operating at 400.13 MHz, or a Bruker DRX-500 instrument 
operating at 500.13 MHz, or a Bruker AVIII-600 instrument operating at 600.13 
MHz.  All 
13
C NMR spectra were recorded on a Bruker DRX-400 instrument 
operating at 100.52 MHz, a Bruker DRX-500 instrument operating at 125.77 MHz, or 
a Bruker AVIII-600 instrument operating at 150.92 MHz.  Chemical shifts are 
reported in ppm relative to the residual protonated solvent peak.  Electrospray 
ionization mass spectrometry (ESI-MS) experiments were done with a JEOL 
AccuTOF spectrometer with an Agilent 1100 HPLC interface.  Chromatography was 
performed using 60-200 mesh silica gel from Baker.  Thin layer chromatography was 
performed on Uniplate
TM
 Silica Gel GF silica-coated glass plates and visualized by 
UV lamp and ceric ammonium molybdate (CAM) stain.  The pH of solutions was 
monitored with a Fisher Scientific AR25 dual channel pH/ion meter.  Liposome 
fluorometric assays were recorded using a Hitachi F-4500 spectrophotometer.  
Sphingolipids, egg-yolk phosphatidylcholine (EYPC) lipids, Nucleopore 
polycarbonate membranes, and membrane supports were purchased from Avanti 
Polar Lipids.  High-pressure extrusion was performed using an Avanti mini-extruder.  
Size-exclusion chromatography was performed using Sephadex G25 (lucigenin), 
Sephacryl S200 (carboxyfluorescein), or Sephacryl S300HR (FITC-dextrans).  
Deuterated solvents were purchased from Cambridge Isotope Labs.  All other 




used without further purification.  X-ray crystal structures were obtained on a Bruker 
Smart1000 diffractometer with CDD area detector by Dr. Peter Y. Zavalij. 
 
6.2 Synthetic Procedures 
p-Methoxybenzylidene C16-ceramide (C16-pmb 14):   
C16-ceramide 1 (Avanti Polar Lipids, 
10 mg, 18.6 mol) was added to 
solution of p-anisaldehyde (0.56 g, 
41.1 mol) and ZnCl2 (6 mg, 44.0 
mol) in dry methylene chloride (1.5 
mL).  The reaction mixture was stirred over molecular sieves at 25 
o
C under N2 
overnight.  Solid NaHCO3 was then added to the reaction mixture and the resulting 
mixture was stirred for 5 min and filtered.  Hexanes was added to the reaction mixture 
causing a white solid to precipitate out of solution.  The white precipitate was filtered 
off to give pure C16-pmb 14 (9.8 mg, 80 % yield).  M.p. 131-133 °C; IR (neat) 3270, 




H-NMR (600 MHz, CDCl3) δ = 7.42 (d, 2H, J = 8.7 
Hz), 6.88 (d, 2H, J = 8.7 Hz), 5.81 (dt, 1H, J = 15.4 Hz, J = 6.7 Hz), 5.52 (dd, 1H, J = 
15.4 Hz, J = 7.3 Hz), 5.48 (s, 1H), 5.01 (d, 1H, J = 7.6 Hz), 4.39 (dd, 1H, J = 4.4 Hz, 
J = 10.5 Hz), 4.04 (m, 2H), 3.80 (s, 3H), 3.58 (d, 1H, J = 10.5 Hz), 2.14 (m, 2H), 2.04 
(m, 2H), 1.59 (m, 6H), 1.40-1.20 (m, 42H), 0.89 (t, 6H, J = 7.0 Hz); 
13
C NMR (100 
MHz, CDCl3) δ = 173.3, 160.5, 137.6, 130.6, 128.0, 126.9, 114.1, 101.7, 82.3, 70.1, 
55.7, 47.23, 37.3, 32.8, 32.3, 30.2, 30.1, 30.0, 29.8, 29.7, 29.4, 26.1, 23.1, 14.5; ESI-
MS [M+H]
+
 calculated for C42H74NO4
+




p-Methoxybenzylidene C2-ceramide (C2-pmb 15):   
C2-ceramide 2 (Avanti Polar Lipids, 
10 mg, 29.3 mol) was added to 
solution of p-anisaldehyde (0.56 g, 
41.1 mol) and ZnCl2 (6 mg, 44.0 
mol) in dry methylene chloride (1.5 
mL).  The reaction mixture was stirred over molecular sieves at 25 
o
C under N2 
overnight.  Solid NaHCO3 was then added to the reaction mixture and the resulting 
mixture was stirred for 5 min and filtered.  The crude reaction product was then 
purified by SiO2 column chromatography using a solvent system of 2% MeOH in 
CH2Cl2 to afford the C2-pmb 15 (9.0 mg, 67 % yield).  M.p. 149-150 °C; IR (neat) 




H-NMR (400 MHz, CDCl3) δ = 7.42 (d, 2H, J = 
8.7 Hz), 6.89 (d, 2H, J = 8.7 Hz), 5.82 (dt, 1H, J = 15.4 Hz, J = 6.8 Hz), 5.53 (dd, 1H, 
J = 15.4 Hz, J = 7.2 Hz), 5.48 (s, 1H), 5.05 (d, 1H, J = 7.4 Hz), 4.40 (dd, 1H, J = 4.4 
Hz, J = 10.5 Hz), 4.03 (m, 2H), 3.80 (s, 3H), 3.58 (t, 1H, J = 10.5 Hz), 2.06 (m, 2H), 
1.97 (s, 3H), 1.57 (m, 6H), 1.40-1.20 (m, 16H), 0.89 (t, 3H, J = 7.1 Hz); 
13
C NMR 
(100 MHz, CDCl3) δ = 170.0, 160.3, 137.4, 130.4, 127.8, 126.7, 113.9, 101.5, 82.0, 
69.8, 59.7, 55.5, 47.3, 38.4, 32.6, 32.1, 31.5, 29.9, 29.8, 29.7, 29.6, 29.4, 29.2, 23.6, 
22.9, 14.4; ESI-MS [M+H]
+
 calculated for C28H46NO4
+
 460.343, found 460.365. 







1,3-diacetyl C2-ceramide (C2-diacetate 16):   
C2-ceramide 2 (Avanti Polar 
Lipids, 10 mg, 29.3 mol) was 
added to solution of acetyl 
chloride (6.9 mg, 87.8 mol) 
and triethylamine (8.9 mg, 87.8 mol) in dry methylene chloride (1.5 mL).  The 
reaction mixture was stirred at 25 
o
C under N2 overnight.  Solid NaHCO3 was then 
added to the reaction mixture and the resulting mixture was stirred for 5 min and 
filtered.  The crude reaction product was then purified by SiO2 column 
chromatography using a solvent system of 2% MeOH in CH2Cl2 to afford the C2-
diacetate 16 (8.7 mg, 70 % yield).  M.p. 102-103 °C (lit. 104-105 °C);240 IR (neat) 




H-NMR (400 MHz, CDCl3) δ = 5.80 (dt, 
1H, J = 15.4 Hz, J = 7.2 Hz), 5.64 (d, 2H, J = 9.2 Hz), 5.40 (dd, 1H, J = 15.4 Hz, J = 
7.5 Hz), 5.29 (dd, 1H, J = 11.7 Hz, J = 7.5 Hz), 4.44 (m, 1H), 4.31 (dd, 1H, J = 11.6 
Hz, J = 6.0 Hz), 4.05 (dd, 1H, J = 11.6 Hz, J = 3.9 Hz), 2.08 (s, 3H), 2.07 (s, 3H), 
2.03 (m, 2H), 1.99 (s, 3H), 1.40-1.20 (m, 22H), 0.89 (t, 3H, J = 6.8 Hz); 
13
C NMR 
(100 MHz, CDCl3) δ = 171.0, 170.1, 169.5, 137.4, 124.3, 73.7, 62.6, 50.9, 32.2, 32.0, 
29.8, 29.6, 29.5, 29.4, 29.1, 14.3; ESI-MS [M+H]
+
 calculated for C24H44NO5
+
 








Isopropylidene C2-ceramide (18):   
C2-ceramide 1 (Avanti Polar Lipids, 
10.5 mg, 30.7 mol) was added to 
solution of p-TsOH∙H2O (2.3 mg, 12.3 
mol) in acetone (1 mL) and 2,2’-dimethoxypropane (1 mL).  The reaction mixture 
was stirred at 25 
o
C under N2 overnight.  Solid NaHCO3 was then added to the 
reaction mixture and the resulting mixture was stirred for 5 min, filtered and 
concentrated in vacuo.  The crude reaction product was then purified by SiO2 column 
chromatography using a solvent system of 2% MeOH in CH2Cl2 to afford the 
isopropylidene C2-ceramide 18 (11.0 mg, 94 % yield).  M.p. 68.0-69.5 °C; IR (neat) 






NMR (400 MHz, CDCl3) δ = 5.75 (td, 1 H, J 
= 6.7, J = 15.2 Hz), 5.43 (dd, 1 H,  J = 7.6, J = 15.2 Hz), 5.21 (d, 1 H, J = 8.0 Hz), 
4.06 (dd, 1 H, J = 7.6, J = 9.2 Hz), 4.01 (dd, 1 H, J = 5.3, J = 11.3 Hz), 3.84 (m, 1H), 
3.63 (dd, 1 H, J = 9.3, J = 11.3 Hz), 2.04 (m, 2 H), 1.94 (s, 3 H), 1.49 (s, 3 H), 1.42 
(s, 3 H), 1.25 (m, 22 H), 0.88 (t, 3H, J = 6.8 Hz); 
13
C NMR (100 MHz, CDCl3) δ = 
170.0, 136.8, 127.5, 99.1, 74.4, 63.0, 48.5, 32.6, 32.1, 29.9, 29.9, 29.8, 29.7, 29.6, 
29.4, 29.2, 28.7, 23.6, 22.9, 20.2, 14.3;  ESI-MS [M+H]
+
 calculated for C23H44NO3
+
 









Trifluoroacetyl C2-ceramide (19): 
Trifluoroacetic anhydride (7.0 mg, 
33.4 mol) was added dropwise to 
a solution of D-erythro-
sphingosine 3 (Avanti Polar Lipids, 10 mg, 33.4 mol) and triethylamine (3.4 mg 
mol) in methylene chloride (2 mL).  The reaction mixture was stirred at 25 
o
C under 
N2 overnight.  Solid NaHCO3 was then added to the reaction mixture and the resulting 
mixture was stirred for 5 min, filtered and concentrated in vacuo.  The crude reaction 
product was then purified by SiO2 column chromatography using a solvent system of 
4.5% MeOH in CH2Cl2 to afford the trifluoroacetyl C2-ceramide 19 (8.6 mg, 59 % 







NMR (400 MHz, CDCl3) δ = 7.15 (d, 1H, J = 7.3 Hz), 5.83 (dt, 1H, J = 
15.4 Hz, J = 7.1 Hz), 5.54 (dd, 1H, J = 15.4 Hz, J = 6.5 Hz), 4.39 (t, 1H, J = 6.5 Hz), 
4.11 (dd, 1H, J = 11.5 Hz, J = 2.3 Hz), 3.93 (m, 1H), 3.74 (dd, 1H, J = 11.5, 3.3 Hz), 
2.43 (br. s, 1H), 2.37 (br. s, 1H), 2.07 (m, 2H), 1.50-1.20 (m, 22H), 0.88 (t, 3H, J = 
6.8 Hz); 
13
C NMR (100 MHz, CDCl3) δ = 157.4 (q, JCF= 37.2 Hz), 135.6, 128.2, 
116.1 (q, JCF = 287.5 Hz), 74.4, 61.3, 54.2, 32.4, 32.1, 29.9, 29.8, 29.7, 29.6, 29.4, 
29.2, 22.9, 14.3; ESI-MS [M+H]
+
 calculated for C20H37F3NO3
+









6.3 Carboxyfluorescein (CF) Liposome Assays 
6.3.1 Liposome Preparation 
A stock solution of EYPC in CHCl3 (60 mg in 3 mL) was evaporated under reduced 
pressure to produce a thin film that was dried in vacuo overnight.  The lipid film was 
hydrated with a 1 mL solution containing 10 mM HEPES (pH 7), 38.8 mM NaCl, 1 
mM EDTA, 1.5 mM CF, and 6 mM p-xylene-bis-pyridinium bromide (DPX).  
Freeze/thaw cycles were repeated 9 times, at which time no solids were visible. The 
frozen solution was warmed to 30-35 
o
C before each freeze cycle.  The mixture was 
placed on a vortexer every 3 cycles for 30 seconds to facilitate hydration.  The cloudy 
solution was extruded through a 100 nm polycarbonate membrane at least 25 times at 
room temperature using a high pressure mini-extruder.  This solution was passed 
through a Sephacryl S200 column (11 cm x 1 cm) using a buffer containing 10 mM 
HEPES (pH 7), 50 mM NaCl, and 1 mM EDTA as the eluant to remove 
extravesicular CF and DPX.  The 6-10 mL of solution isolated from gel filtration was 
8-12 mM in lipid, assuming all EYPC was incorporated into the liposomes. Each 
stock solution of liposomes was used within three days for dye release assays. 
 
6.3.2 CF Dye Release Assay 
47
 
This procedure describes a typical ion transport assay as described in Chapter 2.  An 
aliquot (volume varies depending on concentration of stock solution, typically 100-
180 L) of the stock solution of EYPC liposomes was added to a cuvette and diluted 
to 2 mL with a solution containing 10 mM HEPES (pH 7), 50 mM NaCl, and 1 mM 




intravesicular CF was monitored by excitation at 495 nm, and the emission was 
recorded at 520 nm.  At t = 30 s, compounds were injected into the liposomal solution 
to give a final concentration of compound added of 50 M (15 mol% of compound 
relative to EYPC phospholipid).  At the end of the experiment, 40 mL of a 10% 
aqueous Triton-X solution was injected to lyse the liposomes.  All data presented is 
an average of 3 runs. 
 
6.4 FITC-Dextran Liposome Assays 
6.4.1 Liposome Preparation 
A stock solution of EYPC in CHCl3 (60 mg in 3 mL) was evaporated under reduced 
pressure to produce a thin film that was dried in vacuo overnight.  The lipid film was 
hydrated with a 1 mL solution containing 10 mM HEPES (pH 7), 100 mM KCl, 7.5 
mM fluorescent isothiocyanate (FITC) dextran FD10.  At these concentrations, the 
fluorescence of FD10 is self-quenched.
81
  Freeze/thaw cycles were repeated 9 times, 
at which time no solids were visible. The frozen solution was warmed to 30-35 
o
C 
before each freeze cycle.  The mixture was placed on a vortexer every 3 cycles for 30 
seconds to facilitate hydration.  The cloudy solution was extruded through a 100 nm 
polycarbonate membrane at least 25 times at room temperature using a high pressure 
mini-extruder.  This solution was passed through a Sephacryl S300HR column (11 
cm x 1 cm) using a buffer containing 10 mM HEPES (pH 7), and 100 mM KCl as the 
eluant to remove extravesicular dye.  The 6-10 mL of solution isolated from gel 




liposomes. Each stock solution of liposomes was used within three days for dye 
release assays. 
 
6.4.2 FITC-Dextran Release Assay 
This procedure describes a typical ion transport assay as described in Chapter 2.  An 
aliquot (volume varies depending on concentration of stock solution, typically 10-30 
L) of the stock solution of EYPC liposomes was added to a cuvette and diluted to 2 
mL with a solution containing 10 mM HEPES (pH 7), and 100 mM KCl give a final 
concentration of 70 M phospholipid. The fluorescence of intravesicular FD10 was 
monitored by excitation at 495 nm, and the emission was recorded at 520 nm.  At t = 
30 s, compounds were injected into the liposomal solution to give a final 
concentration of compound added of 50 M (70 mol% of compound relative to 
EYPC phospholipid).  At the end of the experiment, 40 mL of a 10% aqueous Triton-
X solution was injected to lyse the liposomes.  All data presented is an average of 3 
runs. 
 
6.5 Lucigenin Liposome Assays 
6.5.1 Liposome Preparation 
A stock solution of EYPC in CHCl3 (60 mg in 3 mL) was evaporated under reduced 
pressure to produce a thin film that was dried in vacuo overnight.  The lipid film was 
hydrated with a 1 mL solution containing 20 mM HEPES (pH 7.4), 100 mM NaCl 
and 2 mM lucigenin.  Freeze/thaw cycles were repeated 9 times, at which time no 
solids were visible. The frozen solution was warmed to 30-35 
o




cycle.  The mixture was placed on a vortexer every 3 cycles for 30 seconds to 
facilitate hydration.  The cloudy solution was extruded through a 100 nm 
polycarbonate membrane at least 25 times at room temperature using a high pressure 
mini-extruder.  This solution was passed through a Sephadex G25 column (11 cm x 1 
cm) to remove extravesicular lucigenin.  The eluant was comprised of 20 mM HEPES 




.  The 6-10 mL 
of solution isolated from gel filtration was 8-12 mM in lipid, assuming all EYPC was 
incorporated into the liposomes. Each stock solution of liposomes was used within 
three days for transport assays. 
 
6.5.2 Anion Transport Assay 
This procedure describes a typical ion transport assay as described in Chapters 3 and 
4.  An aliquot (volume varies depending on concentration of stock solution, typically 
80-120 L) of the stock solution of EYPC liposomes was added to a cuvette and 
diluted to 2 mL with a solution of salt NaX and 20 mM HEPES at pH 7.4 to give a 
final concentration of 200 M phospholipid. The fluorescence of intravesicular 
lucigenin was monitored by excitation at 372 nm, and the emission was recorded at 
503 nm.  At t = 30 s, a 2 µL aliquot of a 2 mM stock solution of the compound being 
tested (or a DMSO blank) was injected to give a final concentration of compound 
added of 2 M (1 mol% of compound relative to EYPC phospholipid).  At the end of 
the experiment, 40 mL of a 10% aqueous Triton-X solution was injected to lyse the 





6.6 Direct Monitoring of Bicarbonate Transport via 
13
C NMR 
6.6.1 Liposome Preparation 
A stock solution of EYPC in CHCl3 (280 mg in 14 mL) was evaporated under 
reduced pressure to produce a thin film that was dried in vacuo overnight.  The lipid 
film was hydrated with a 2 mL solution containing 20 mM HEPES (pH 7.4), 100 mM 
NaH
13
CO3 in 9:1 H2O/D2O.  Freeze/thaw cycles were repeated 9 times, at which time 
no solids were visible. The frozen solution was warmed to 30-35 
o
C before each 
freeze cycle.  The mixture was placed on a vortexer every 3 cycles for 30 seconds to 
facilitate hydration.  The cloudy solution was extruded through a 5 m polycarbonate 
membrane at least 25 times at room temperature in two separate 1 mL batches.  The 
two batches were then combined and added to dialysis tubing.  The dialysis tubing 
containing the liposome solution was submerged in a 1 L solution containing 20 mM 
HEPES (pH 7.4) and 75 mM Na2SO4 in 9:1 H2O/D2O.  This solution was stirred for 4 
hours to allow SO4
2-




.  Each stock solution of 




C NMR Bicarbonate Transport Assays 
This procedure describes a typical ion transport assay as described in Chapter 4.  
13
C 
NMR spectra were recorded on a Bruker AVIII-600 operating at 150.92 MHz, with 
chemical shifts reported in ppm.  The instrument was locked on 9:1 H2O/D2O.  
Experimental conditions were: temperature, 27 °C; acquisition time, 0.93 s; spectrum 
width 35,211 Hz; relaxation delay, 0.2 s; number of scans, 196.  For each experiment, 
an initial 
13




solution consisted of EYPC liposomes containing 100 mM NaH
13
CO3 buffered to pH 
7.4 with 20 mM HEPES, dispersed in 75 mM Na2SO4 buffered to pH 7.4 with 20 mM 
HEPES.  A NaCl pulse followed, resulting in final extravesicular concentrations of 41 
mM lipid and 50 mM NaCl.  The 
13
C NMR of this liposome mixture was taken, 
followed by the addition of a solution of compound (in DMSO, 15 µL) or 15 µL of 
DMSO.  Compounds were added to give a 0.04 molar equiv. to lipid ratio.  A 
13
C 
NMR of the ligand containing mixture was acquired before and after the addition 3 




6.7 X-Ray Crystallographic Data 
6.7.1 C2-pmb 15 
Crystals were obtained by slow evaporation of a DMSO solution of C2-pmb 15, and 
the structure (Figure 6.1) was solved by Dr. Peter Y. Zavalij.  Table 6.1 shows 
crystal data and structure refinement parameters for C2-pmb 15.  Detailed 
crystallographic data and the structure report for UM1807 (C2-pmb 15) can be 
obtained from the Department of Chemistry and Biochemistry, University of 





Figure 6.1.  A view of UM#1807 showing the anisotropic atomic displacement 
ellipsoids for the non-hydrogen atoms are shown at the 25% probability level. 












Table 6.1. Crystal data and structure refinement for UM#1807. 
____________________________________________________________________________________________ 
 X-ray lab book No. 1807  
 Crystal ID Davis/Harrell pMBC2 at 295K =1804 (same xtal) 
 Empirical formula C28H45NO4 
 Formula weight 459.65 
 Temperature 295(2) K 
 Wavelength 0.71073 Å 
 Crystal size 0.45  0.20  0.06 mm3 
 Crystal habit colorless plate 
 Crystal system Monoclinic 
 Space group P21 
 Unit cell dimensions a = 9.4304(5) Å  = 90° 
 b = 4.9089(3) Å  = 91.2750(10)° 
 c = 30.3484(16) Å  = 90° 
 Volume 1404.57(14) Å3 
 Z 2 
 Density, calc 1.087 g/cm
3 
 Absorption coefficient,  0.071 mm-1 
 F(000) 504e  
 Diffractometer Bruker Smart Apex II CCD area detector 
 Radiation source fine-focus sealed tube, MoK 
 Detector distance 6.000 cm  
 Detector resolution 8.333 pixels/mm  
 Total frames 2100  
 Frame size 512 pixels  
 Frame width -0.30° 
 Exposure per frame 60 sec 
 Total measurement time 38.5 hours 
 Data collection method  and  scans  
  range for data collection 2.01 to 25.00° 
 Index ranges -11  h  11, -5  k  5, -36  l  35 
 Reflections collected 11341 
 Independent reflections 2789 
 Observed reflection, I>2(I) 2125 
 Coverage of independent reflections 99.9 % 
 Variation in check reflections 0 % 
 Absorption correction Semi-empirical from equivalents 
 SADABS (Sheldrick, 1996) 
 Max. and min. transmission 0.996 and 0.949 
 Structure solution technique direct 
 Structure solution program SHELXS-97 (Sheldrick, 1990) 
 Refinement technique Full-matrix least-squares on F2 
 Refinement program SHELXL-97 (Sheldrick, 1997) 
 Function minimized w(Fo
2 - Fc
2)2 
 Data / restraints / parameters 2789 / 238 / 366 
 Goodness-of-fit on F2 0.995 
 /max 0.001 
 Final R indices: R1,   I>2(I) 0.0365 
 wR2, all data 0.0668 
 Rint 0.0220 
 Rsig 0.0176 
 Weighting scheme w = 1/[2(Fo




 Absolute structure parameter not determined 
 Largest diff. peak and hole  0.090 and -0.081e/Å3 
____________________________________________________________________________________________ 








6.7.2 Isopropylidene C2-Ceramide 18 
Crystals were obtained by slow evaporation of a DMSO solution of isopropylidene 
C2-ceramide 18, and the structure (Figure 6.2) was solved by Dr. Peter Y. Zavalij.  
Table 6.2 shows crystal data and structure refinement parameters for isopropylidene 
C2-ceramide 18.  Detailed crystallographic data and the structure report for UM1793 
(isopropylidene C2-ceramide 18) can be obtained from the Department of Chemistry 






Figure 6.2.  A view of 4 symmetrically independent molecules in the unit cell of 
UM#1793. Anisotropic atomic displacement ellipsoids for the non-hydrogen atoms 
are shown at the 30% probability level. Hydrogen atoms are displayed with an 













Table 6.2. Crystal data and structure refinement for UM # 1793 
__________________________________________________________________________________ 
Crystal ID Davis/Harrell C2-ceramide 1,3-isopropylidene 2 150K 
 Empirical formula C23H43NO3 
 Formula weight 381.58 
 Temperature 150(2) K 
 Wavelength 0.71073 Å 
 Crystal size 0.51  0.12  0.06 mm3 
 Crystal habit colorless needle 
 Crystal system Triclinic 
 Space group P1 
 Unit cell dimensions a = 8.9474(16) Å  = 87.563(2)° 
 b = 9.1515(16) Å  = 82.486(2)° 
 c = 29.391(5) Å  = 88.842(2)° 
 Volume 2383.5(7) Å3 
 Z 4 
 Density, calc 1.063 g/cm
3 
 Absorption coefficient,  0.069 mm-1 
 F(000) 848e  
 Diffractometer Bruker Smart Apex II CCD area detector 
 Radiation source fine-focus sealed tube, MoK 
 Detector distance 6.000 cm  
 Detector resolution 8.333 pixels/mm  
 Total frames 4230  
 Frame size 512 pixels  
 Frame width -0.30° 
 Exposure per frame 40 sec 
 Total measurement time 54.0 hours 
 Data collection method  and  scans  
  range for data collection 2.10 to 25.00° 
 Index ranges -10  h  10, -10  k  10, -34  l  34 
 Reflections collected 30116 
 Independent reflections 8310 
 Observed reflection, I>2(I) 6931 
 Coverage of independent reflections 99.1 % 
 Variation in check reflections 0 % 
 Absorption correction Semi-empirical from equivalents SADABS (Sheldrick, 
1996) 
 Max. and min. transmission 0.996 and 0.873 
 Structure solution technique direct 
 Structure solution program SHELXS-97 (Sheldrick, 1990) 
 Refinement technique Full-matrix least-squares on F2 
 Refinement program SHELXL-97 (Sheldrick, 1997) 
 Function minimized w(Fo
2 - Fc
2)2 
 Data / restraints / parameters 8310 / 3 / 989 
 Goodness-of-fit on F2 1.000 
 /max 0.000 
 Final R indices: R1,   I>2(I) 0.0586 
 wR2, all data 0.1290 
 Rint 0.0454 
 Rsig 0.0436 
 Weighting scheme w = 1/[2(Fo
2)+(0.02P)2+3.17P], P = [max(Fo
2 ,0)+2Fo
2]/3 
 Absolute structure parameter unknown 
 Largest diff. peak and hole  0.297 and -0.210e/Å3 
____________________________________________________________________________________________ 
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